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SUMMARY
The distribution, metabolism■and excretion of bifluranol, 
a novel bibenzyl, has been determined in mouse, rat, ferret and 
dog and compared to the fate of diethylstilboestrol. Bifluranol 
is extensively absorbed, but systemic tissue levels are low due 
to hepatic uptake and biliary excretion. After enterohepatic 
recirculation the dose is excreted in the faeces and only small 
amounts appear in urine. This pattern is similar to that reported 
for diethylstilboestrol.
The metabolic fate of bifluranol was found to differ 
considerably from that of diethylstilboestrol. In rat oxidative 
metabolism of bifluranol (4-8%) was considerably lower than that 
reported for diethylstilboestrol (309o). Bifluranol was extensively 
excreted as diconjugates with glucuronic acid and sulphate, in 
contrast to the major conjugate of diethylstilboestrol, the 
monoglucuronide. Preliminary data indicate conjugation of 
bifluranol with phosphate in ferret and dog. Glucuronyl- and 
sulpho-transferase enzyme systems were shown to conjugate both 
bifluranol and diethylstilboestrol. The rate of bifluranol 
conjugation in both systems was > ten-fold higher than with 
diethylstilboestrol and may explain in part the extensive 
diconjugate formation of bifluranol.
The differences in metabolism of bifluranol and 
diethylstilboestrol are discussed in terms of the aromatic 
fluorine substituents of bifluranol.
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CHAPTER 1
BIFLURANOL - HISTORICAL ASPECTS 
AND METABOLIC CONSIDERATIONS
1.1 Historical Aspects
1.2 Metabolism of Hexoestrol and Diethylstilboestrol
1.5 Aromatic Halogen Substitution and Metabolism Mediated 
Toxicity
1.1 Historical Aspects
Sex, until comparatively recent times in mankind*s history 
was a state of affairs to be accepted and enjoyed with little 
systematic consideration of the reasons for the basic differences 
between male and female. The advent of the scientific method 
and its application to the study of mans (and womans) chemical 
makeup has hov/ever changed this. It is now apparent that these 
fundamental differences in anatomical structure can arise from 
small differences in the structures and relative amounts of a 
few molecules within the body.
Previously it had been observed that extracts from testes 
and ovaries were capable of restoring certain secondary sexual 
characteristics in castrated experimental animals. The 
successful isolation of the compounds became possible with the 
development of the vaginal cornification test for oestrogens 
(Allen and Doisy, 1923) and the growth of the comb in capons 
for androgens (Gallagher and Koch, 1929)* Oestrone was the 
first material to be isolated (Doisy, et al, 1929; Butenandt, 1929) 
and this was followed by oestriol (Marrian, 1930)^ androsterone 
(Butenandt, 1931)t progesterone (Butenandt and Westphal, 1934), 
©estradiol (MacCorquodale, et al, 1935) and testosterone 
(David, et al, 1935)* Pure samples of the steroids were 
characterised chemically and their structures determined shortly 
after their isolation (Butenandt, 1932; Wintersteiner and Allen, 
1934; Butenandt and Hanisch, 1935), although the absolute 
configuration of ©estradiol was not confirmed for some time
(Turner, 1950; Gallagher and Kritchev.sky, 1950).
The oestrogenic hormones isolated were potentially useful 
as contraceptive agents, but it was found that they lacked oral 
activity and had to be administered parenterally. A search for 
synthetic oestrogens started and, following the observation 
that 1-keto 1 ,2,3,4 tetrahydrophenanthrene was a weak oestrogen 
(Cook, et al, 1933) and that all the oestrogenic hormones had a 
cyclopentenohexahydrophenanthrene ring structure (Dodds, 1937) , 
attempts were made to see how far one could depart from the 
structure of natural oestrogens and still retain oestrogenic 
activity. The development of syntheses had led to 4,4 - 
dihydroxystilbene and p-hydroxypropylbenzene was prepared as a 
simplification of this structure and found to be oestrogenic. 
Subsequently it was shown that this activity was due to a 
highly oestrogenic contaminant which proved to be the stilbene 
diethylstilboestrol (Dodds, 1969). The production of this and 
the two structurally similar compounds hexoestrol and dienestrol 
(Figure 1.1) provided materials of comparable or greater 
activity than oestradicl. Their most important feature 
however was that, unlike the natural oestrogens, they were active 
by the oral route (Dodds, et al, 1938a). Several analogues 
were produced subsequently and it was shown that the phenanthrene 
ring base was not essential for oestrogenicity, but none of 
these later compounds were as potent as diethylstilboestrol 
(Dodds, et al, 1958b,c). Many analogues of stilbene and 
bibenzyl structures have been produced since this early work 
and their pharmacological activity reviewed (Emraens, 1970).
Figure 1.1 Structures of oestfadiol, diethylstilboestrol, 
hexoestrol, dienoestrol and bifluranol
OH
Oejstradiol
Diethylstilboestrol
Hexoestrol
OH
DienoestrolHO
Bifluranol (erythro-3,3 - 
difiuoro-4,4 -dihydroxy- 
OC-methyl-a -ethyl bibenzyl )
However, none of these compounds have to date been able to compete 
successfully with the original discoveries.
It is of importance at this stage to note the difference 
between stilbene structures such as diethylstilboestrol, which are 
based on phenanthrene, and the bibenzyl structures, such as 
hexoestrol, where two phenols are joined by a saturated carbon 
chain. The central double bond of stilbenes not only imparts a 
different conformation to the molecule, but also allows electron 
delocalisation throughout the structui'e and provides an additional 
> site for oxidative metabolism in vivo (Metzler, 1976).
Syntheses of steroids and their derivatives continued during 
this period, but in the field of sex steroids the only notable 
immediate success was with» ethynyloestradiol and mestranol 
(Inhoffen, et al, 1938), which were highly active orally. Despite 
extensive modifications to the basic steroid structure, the next 
major advance in this fiej.d did not come until the discovery of 
the norsteroids (Djerassi, et al, 1934; McGinty and Djerassi, 1958), 
which produced many orally active progestational compounds and 
opened the way for the development of an oral steroidal 
contraceptive pill.
The major novel departure in modifying steroid structures 
w a s  achieved with the corticosteroids by the introduction of 
halogens, notably fluorine, into the steroid nucleus. Side 
effects in the treatment of rheumatoid arthritis with cortisone 
had limited the drugs usefulness and modifications to the
structures were being made in an attempt to improve the drug.
These had been largely unsuccessful until a 9-bromo derivative 
was found to possess unexpected cortisol like activity 
(Fried, et al, 1955)» The substitution of other halogen atoms 
quickly followed and the relative activities for the 9-halogenated 
cortisol acetate derivatives were 0 .1  (iodo-), 0 .2 8 (bromo-),
4,7 (chloro-) and 10.7 (fluoro-). Unfortunately, whilst the 
9-fluoro- derivative was effective at one tenth the dose of 
cortisol acetate, it also possessed high mineralocorticoid 
activity which limited the drugs usefulness. Despite this 
initial disappointment, subsequent work produced;potent 
fltiorocorticosteroids with high anti-inflammatory activity 
and low mineralocorticoid activity.
Some important concepts in drug design are demonstrated 
within this brief review. Diethylstilboestrol and hexoestrol 
are drugs based on attempts to mimic what were thought to be 
active areas of a natural hormone and this search gave rise to 
novel structures with similar activity to oestradiol, but which 
were also active orally. Many stilbene and bibenzyl structures 
were subsequently prepared based on these original discoveries. 
The halogenated corticosteroids were based on modification of a 
known biological entity, with the result that biological 
activity was greatly enhanced by fluorine or chlorine 
incorporation. Subsequent alterations demonstrated .that it was 
possible to separate and alter the relative biological activities 
of compounds with more than one biological activity. Several 
hundred steroids containing various modifications have been
produced in attempts to obtain desirable combinations of 
biological activity and many of these compounds have therapeutic 
usefulness (for a summary of structures and activities see 
Appelsweig, 1964).
There has been no systematic examination of the effects of 
liaLiogcn insertion into bibenzyl structures, essentially a 
combination of the two above approaches, until the recent series 
of compounds produced by Biorex Laboratories Ltd. (British 
Patent Nos. 128076? and l4l6648). Several compounds have been 
produced and the effect of halogens on the oestrogenic, 
anti—oestrogenicandrogenic and anti-androgenic properties of 
the basic bibenzyl structure have been studied. One of these 
compounds, bifluranol (Figure 1.1) was found to possess oral 
anti—androgenic properties similar to those of diethylstilboestrol 
but with only one eighth of the oestrogenic activity in rodents 
(Dekanski, personal communication). Anti-androgenicity of 
diethylstilboestrol has previously been correlated with 
oestrogenicity, but with these bibenzyl structures some 
separation of these activities has been achieved.
Diethylstilboestrol is used to treat prostatic enlargement 
as an alternative to surgical intervention (Lambley and Ware, 
1967). However, in addition to feminising effects, it has been
shown that whilst patients receiving diethylstilboestrol showed
some improvement in the prostate condition, overall prognosis 
was not improved due to circulatory disorders, presumably arising 
from oestrogenic activity (Veterans A.C.Ü.E.G., 1967)*
view of the lower oestrogenic potency of bifluranol and its 
comparable anti-androgenic activity, bifluranol is currently 
undergoing clinical evaluation for treatment of prostatic 
enlargement.
Apart from the aromatic fluorine substituents, bifluranol 
is chemically similar to hexoestrol and, allowing for the 
stilbene double bond, diethylstilboestrol# Many foreign 
compounds of similar structure have a similar distribution 
and metabolic pattern in vivo and a consideration of the fate 
of hexoestrol and diethylstilboestrol is therefore of relevance 
to the metabolic fate of bifluranol.
1.2 Metabolism of hexoestrol and diethylstilboestrol
Few studies have been carried out on the metabolism of 
hexoestrol. Studies in rat and rabbit demonstrated excretion 
of drug in both faeces and urine, with the rat showing 
predominantly faecal excretion and the rabbit urinary excretion. 
Overall recoveries of administered drug were variable, with up to 
90% being recovered after 96 hours. Total oxidation was 
reported as 2% or less, although no attempts were made to show 
that aromatic hydroxylation had not occurred and the identity 
of the excreted drug was not established (Dodds, et al, 1958). 
Studies in cattle, sheep and goats showed that systemic drug 
levels were maximal between 2 and 6 hours after drug 
administration, with tissue uptake by liver, kidney, uterus, 
mammaries, vagina and lungs. Hexoestrol and glucui'onide and
sulphate conjugates were reported in the sheep reproductive 
tract. In cattle 60% of a dose was excreted in urine, but there 
has been no systematic investigation of the distribution and 
excretion of hexoestrol (Glascock and Hoekestra, 1959a, 1959b; 
Burgos-Gonzalez and Glascock, 1 96 0).
In contrast several studies have been carried out on the 
metabolism of diethylstilboestrol. Excretion was first reported 
in rabbits (Stroud, 1939) and dogs (Dingemanse and Tyslowitz, >
1941), where up to 25% of the administered drug was recovered 
in the urine, and accumulation by the liver and elimination in 
the bile were observed. The glucuronide was isolated from 
rabbit urine (Mazur and Shorr, 1942) and the first attempts at 
quantitative determination of excretion showed that an average 
of 71% of the administered dose vras excreted in the urine as 
the glucuronide (Dodgson, et al, 1948). However, this finding 
was based on an increased output of glucuronic acid, and dose 
levels were well in excess of those required for physiological 
activity.
The synthesis of radioactively labelled diethylstilboestrol 
allowed assessment of excretion at lower dose levels and several 
studies have been conducted (Table 1.1). The major excretory 
pathway is the faeces in most species studied to date except 
monkey, chimp, swine and man. Biliary excretion is significant 
in rat, guinea pig and hén and probably occurs to some degree in most 
species. The final excretion from the body of diethylstilboestrol 
is retarded in rats by extensive enterohepatic circulation,
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although the importance of this process in other species has 
not been established (Clark, et al, 1969)»
Studies on the tissue distribution of radioactive 
diethylstilboestrol in rodents demonstrated that the major 
localisations of radioactivity were in the liver and 
gastrointestinal tract. Other systemic tissue levels and blood 
levels were low. However, radioactivity was shown to reach all 
tissues of the body, including the foetus, where retention of 
drug may occur (Bengtsson and Ullberg, 1 9 6 3; Shah and McLachlan, 
1976; Neumann, 1976).
The major metabolic reaction of diethylstilboestrol was 
shown to be conjugation with glucuronic acid to give the 
monoglucuronide, although other reactions, primarily with sulphate, 
have been reported (Figure 1.2). Phase 1 metabolism in rat, 
hamster and"man involves a number of oxidation reactions which 
give rise to several metabolites, with the major products in 
rat, the catechols, undergoing Phase 2 méthylation by  ^
catechol-O-methyl transferase:(Figure 1.3, after Metzler, 1976).
■ Rat liver is capable of performing come of the hydroxylation 
and méthylation reactions (Engel, et al. 1976), although other 
sources, such as the intestinal microflora, have been implicated 
in the oxidative degradation of diethylstilboestrol in cattle 
(Aschbacher, 1976).
Toxicological studies with diethylstilboestrol have 
demonstrated a number of effects on organs and tissues of
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experiraental animals. Hepatic centrilobular necrosis was shown 
to occur with ferrets in comparative studies between bifluranol 
and diethylstilboestrol in these laboratories. At a dose level 
of 6mg/kg/day all ferrets receiving diethylstilboestrol had died 
before any deaths occurred in the bifluranol group. Post mortem 
examination showed extensive hepatic centrilobular necrosis in 
diethylstilboestrol treated animals which was not present in 
bifluranol treated animals (Dekanski, et al, in press).
Diethylstilboestrol has been shown to bind to DNA in vivo, 
and also ^  vitro using microsomal preparations, although the 
site of diethylstilboestrol attachment has not been established 
(Blackburn, et al, 1976). Commercially available 
diethylstilboestrol is in the trans configuration, but studies 
by Metzler (1976) have demonstrated that the cis isomer is 
present in samples from ^  vivo studies. This configuration is 
in some respects similar to that of phenanthrene (although the 
diethylstilboestrol is not planar) (Figure 1.4), and the 
carcinogenic and cytotoxic properties of this compound have been 
associated with the formation of a 'K region* epoxide (Grover and 
Sims, 1970). If the oxidation of diethylstilboestrol involves 
the ci^ configuration, this may provide a mechanism for some of 
the cytotoxic effects (liver, kidney and adrenal damage) reported 
with diethylstilboestrol (Grurabrecht and Loeser, 1939; Loeser, 
1939; Selye, 1939).
15
Fleure 1.4 Structures of trans-and cis^diethylstilboestrol 
and phenanthrene
OH trans-diethylstilboestrol
HO
cis-diethylstilboestrol
•K* région
phenanthrene
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1,3 Aromatic Haloeen Substitution and Metabolism Mediated
Toxicity
Hexoestrol and diethylstilboestrol are phenols and the 
conjugation and oxidation reactions of these compounds are 
similar to those reported for phenol (Capel, et al, 1972).
Chloro- bromo- and iodo- phenols produce glucuronide conjugates 
(Kamil, et al, 1951), whilst chlorophenol also gives sulphate 
conjugates (Spencer and Williams, 1950) and a mercapturic acid 
conjugate was reported for bromophenol (Stekol and Dash, 1959).
Fev/ studies have been carried out on the metabolism of halophenols, 
however.
The pattern of Phase 2 conjugation of phenols with 
glucuronic acid and sulphate does not appear to be significantly 
altered by halogen substitution, nor have these reactions per se 
been implicated in cytotoxicity. However, the conjugation rate of 
2-chlorophenol with glucuronic acid vitro was elevated 8-fold 
compared to phenol (Mulder and van Doom, 1975) , and similar 
alterations in conjugation rates of bifluranol may also occur.
Benzene and fluorobenzene produce less than 2% of mercapturic 
acid conjugates in rabbit urine, compared to around 25% seen with 
other halobenzenes (Azouz, et al, 1952). Chlorobenzene produces 
predominantly mercapturic acid and glucuronide and sulphate 
conjugates, with smaller amounts of diphenols (Lindsay Smith, et al, 
1972). The proposed pathway for the oxidation of chlorobenzene 
is via an arene oxide, which rearranges enzymically or non
17
enzymically to give a variety of products (Figure 1.5). Arene 
oxide formation has been proposed as a general mechanism of 
oxidation of many aromatic structures (Jerina and Daly, 1974). 
Binding of the epoxide to macromolecules has been correlated with 
the extent of liver necrosis arising from tissue binding of 
bromobenzene (Reid, et al, 1975). Comparison of fluorobenzene 
v/ith other halobenzenes in these studies showed that the extent 
of binding to tissues was considerably lower and resulted in a 
lower toxicity. Studies on the effect of fluorine substitution 
on 10-methyl 1 ,2-benzanthracene metabolism indicate that fluorine 
.substitution in the 5 position can eliminate the carcinogenic 
action of this compound, although fluorine substitution in the 
4 position did not remove the carcinogenic action (Miller and 
Miller, I960, 1965). Thus it would appear that aromatic fluorine 
substitution can reduce toxicity arising from oxidative 
metabolism in comparison to other halogen substituents.
The mechanism of carcinogenicity of foreign compounds has 
not been conclusively established, although it is generally 
considered to arise by combination of an "active* metabolite 
with cellular DNA, leading to genetic mutations which in certain 
cells become manifest as cancer. Attempts to rationalise the 
carcinogenic properties of polycyclic aromatics based upon 
sophisticated calculations of molecular orbitals and bond 
characteristics were only partially successful, although it was 
established that electron distribution was not uniform and
certain areas of the molecule, notably the *?& region* , were
< '
more reactive than others (Svartholm, 1942; Pullman and Pullman,
18
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1955)• The concept of proximate and ultimate carcinogens has 
also been proposed as an explanation for experimental 
observations. The carcinogen 7,12-dimethylbenz(a)anthracene has 
been shown to bind to DNA, and the extent of this covalent 
binding correlated with the level of carcinogenicity (Brooks 
and Lawley, 196^). It is thought that the parent hydrocarbon 
is'first converted to a tetrahydrophenanthrene metabolite 
(the proximate carcinogen) which then undergoes epoxidation to 
the ultimate carcinogen, but this theory requires experimental- 
validation (Jerina and Daly, 1977).
Recently, a consideration of biphenyl metabolism has led to 
a proposed rationale as to why only certain compounds should 
be carcinogenic (Parke, 1977). ^-Hydroxylation is the major 
metabolic pathway of biphenyl and 2-hydroxylation occurs only 
to a small degree. Induction of metabolism by drugs such as 
phenobarbitone was found to primarily increase production of 
4-hydroxybiphenyl whereas polycyclic aromatic hydrocarbons also 
stimulated 2-hydroxylation. This enhancement of biphenyl 
2-hydroxylation has been correlated with changes in the 
endoplasmic reticulum towards a cell status more favourably 
disposed toward malignant growth (Parke, 1976). Although the 
precise carcinogenic effect remains unclear, it may involve a 
conversion of microsomal cytochrome P450 to p448 and a change 
of the microsomal glycosyl transferases in favour of the extended 
sialylation of cellular glycoproteins.
Thus while the exact cellular mechanisms of carcinogenicity
20
remain unresolved, and may indeed arise from a combination of 
one or more mechanisms, studies on the metabolism of carcinogens 
has provided a basis for explaining carcinogenesis in terms of 
alkylation of cellular macromolecules. This leads to derangement 
of cell structure and function, which may be manifested as tissue 
damage (e.g. necrosis) or cancer.
The present study of bifluranol is designed to determine 
the metabolic fate of this compound and to compare this with that 
of diethylstilboestrol. The differences in the spectrum of 
pharmacological activity and toxicity of the two compounds suggests 
that there may also be differences in the metabolism of the two 
compounds. The aromatic fluorine substituents would be expected 
to provide new information on the effect of this halogen on the 
metabolism of phenols, since the position of substitution could 
block oxidative metabolism at that point and may alter the 
conjugation of the phenolic hydoxyl groups.
21
CHAPTEB 2
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2.1. INTRODUCTION
2.1.1 Factors affecting absorption
Foreign compound distribution depends on many complex and 
interrelated factors relating to absorption, tissue distribution, 
metabolism and excretion. Theoretically these parameters differ 
for all compounds, although in practice they may be divided into 
broad groups which exhibit similar behaviour ^  vivo. Many of 
the principles governing drug distribution are demonstrated in 
a consideration of the fate of phenol and diethylstilboestrol 
in vivo.
Absorption usually occurs by passive diffusion, the 
rate being governed by the concentration gradient across the 
membrane, the surface area of the membrane and a constant for 
the compound related to molecular structure, lipid solubility 
and degree of ionisation. High lipid solubility and little or 
no ionic charge are necessary for rapid absorption. Phenols are 
only weaicly acidic ( pKa f~*10) and under the pH conditions of the 
gastrointestinal tract would be present as the unionised form 
in the stomach (pH 2) or intestine (pH 6.5)* They are also 
usually highly lipid soluble so both phenol (Capel, et al, .1972) 
and diethylstilboestrol (Fischer, et al, 1966) are readily 
absorbed and appear almost quantitatively in rat urine or faeces 
respectively following oral administration. Factors such as 
surface area available for absorption (far greater in the 
intestine than stomach) , • the presence of food and mucus, and
23
gastrointestinal motility and blood flow, may affect the rate of 
absorption of these compounds but do not affect the extent of 
absorption.
2.1.2 Factors affecting distribution
Distribution is achieved primarily by passive diffusion 
into the bloodstream, the flow of which maintains a concentration 
gradient in favour of absorption and allows the compound access 
to other tissues. The distribution between the blood and 
tissues’, and even within cells, is a dynamic system of 
equilibration processes subject to the same physical rules 
governing absorption. In addition, binding to proteins, as 
observed between diethylstilboestrol and erythrocytes (Axe, 1972), 
may affect this partitioning. Immediately after absorption the 
blood levels of a compound are at their highest as the 
equilibration with the tissues commences. As time passes and 
metabolic transformations and excretion occur blood levels fall 
as new equilibria are constantly being established until 
elimination is complete. This has recently been demonstrated 
for diethylstilboestrol in pregnant mice (Shah and McLachlan, 
1 97 6), where uptake from the blood by the major excretory 
organ (liver) and retention by a target tis.sue (uterus) was 
followed by a fall in blood and tissue levels as the drug was 
excreted.
24
2.1.3 Factors affecting excretion
Phenols are excreted either via the kidney into the urine, 
or via the liver and bile into the intestinal lumen and faeces.
The route of excretion has been shown to be dependent to a 
large extent on molecular weight and polarity. In the rat 
compounds with a molecular weight above 325 1 5p, such as 
diethylstilboestrol glueuronide (Abou el Makarem, et al, 196?)» 
undergo predominantly biliary excretion, whilst compounds of 
lower molecular weight, such as phenol sulphate and glueuronide, 
undergo predominantly urinary excretion (Capel, et al, 1972).
The importance of polarity of a compound for its excretion is 
seen with both diethylstilboestrol and phenol, the former 
requiring conversion to a glueuronide prior to biliary excretion 
(Fischer, et al, 1966). However, polarity and high molecular weighi 
do not automatically guarantee biliary excretion since the polar 
diethylstilboestrol sulphate esters are not excreted as such in 
rat bile (Gregory, et al, 1971; Barford, et al, 1977a).
For compounds of molecular weight below 300 or above 500 the 
two excretory pathways are not compensatory should one become 
blocked, but some compensation does occur for compounds in the 
intermediate molecular weight range (Hirom, et al, 1976). Thus 
the kidney has an active transport mechanism for acidic compounds 
with an upper molecular weight limit around 350 and the liver a 
system for acidic compounds above this molecular weight, possibly 
similar to that for conjugated bile acids (Millburn, et al, I967). 
As observed above, neither phenol nor diethylstilboestrol are
25
excreted in the same form as which they are absorbed, and whilst 
lipophilicity is necessary for absorption, appropriate polarity 
is a prerequisite for excretion.
Once a compound has entered the urine little or no 
reabsorption occurs, so that phenol is completely eliminated by 
the rat in 24 hours (Capel, et al, 1972). Diethylstilboestrol 
is virtually completely eliminated in the bile of rats in 24 
hours (Fischer, et al, 1966) yet far less than this appears in 
the faeces during this time. The major biliary metabolite, 
the monoglucuronide, is poorly reabsorbed from the intestine, 
unlike diethylstilboestrol (Fischer and Millburn, 1970), but 
is labile to bacterial p-glucuronidase found in the rat 
intestine to give free diethylstilboestrol (Clark, et al, 1969), 
which is reabsorbed, returned to the liver and re-excreted. This 
process of enterohepatic circulation greatly slows the elimination 
from the animal body.
2.1.4 Experimental approach
In considering the distribution and excretion of bifluranol, 
the experimental approach must answer the following questions: 
i) How much drug is absorbed?
ii) Where decs the drug go to in the animal body?
iii) What is the major excretory pathway and how much of
the drug is excreted over a given time?
Of the analytical techniques available for assessing drug levels, 
the most widely used method for determining the fate of novel
26
compounds entails the incorporation of a radioactive label, 
which can then be readily followed in the animal body. This 
approach has been adopted for the current study of the 
bibenzyl, bifluranol.
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2.2 EXPERIMENTAL
2.2.1 Chemicals
1,4-Dioxan and thixotropic gel powder (Cab-o-sil) were 
supplied by Packard Instruments Ltd., Caversham, England. All 
other chemicals were of Analar grade, where possible, as supplied 
by EcD.H. Chemicals, Poole, Dorset, England.
2.2.2 Radiochemicals
? * I ’ 3 /
"^H-Bifluranol (erythro-3,3 -difluoro-4,4 -dihydroxy-3,3 - H-o4- 
methyl-c«C-ethyl bibenzyl) was prepared at the Radiochemical Centre,: 
Amersham, England. The label was introduced by reduction of
I t t 1 -
erythro-3,3 -difluoro-4,4 -dihydroxy-3,3 -dihromo-c4methyl-o4-ethyl
3 .bibenzyl using tritium gas (Figure 2.1). The H-bifluranol was 
purified by thin layer chromatography in the solvent system 
benzene/ether (1/1) and had a specific radioactivity of 123 Ci/g. 
Radiochemical purity assessed by thin layer chromatography and 
radioassay in the solvent systems n-butanol/acetic acid/water (4/1/1), 
n-propanol/ammonia (s.g. 0.88) (7/3) and <40° petrol/ether (1/1) 
was greater than 97%. The label of bifluranol (230ng/ml, 60pC) 
was shown to be stable under nitrogen in aqueous acid (2M HCl) or 
alkali (2M sodium hydroxide) over a period of 48 hours. Less than 
0.39^ of total label was found to be volatile on drying the 
acidified aqueous phase after ethyl acetate extraction (3 x Irai,
>99% extraction) of the bifluranol.
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%
Figure 2>1 Synthesis of "^H-bifluranol (erythro-
I I * 5
3t3 -difluoro-4,4 -dihydroxy-^,^ - H-
I
oC-methyl-oC -ethyl bibenzyl
HO
Q OH Bifluranol
Brg / CHClj at
room temperature
OH
O Q
+ ethyl acetate 4^ 
triethylamine + 10% 
palladium on charcoal
H -Bifluranol
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2.2.3 Animals
Albino mice (24-28g body wt., males age 4 weeks, females 
age 6 weeks; pregnant mice mated at 6 weeks, used at day l8) 
bred at Biorex Laboratories were used. The colony was 
established from an original strain of Swiss albino mice in 
1972. They were housed in small plastic cages with sawdust 
bedding. Albino rats (200g body wt., males age 6 weeks, females 
age 8 weeks; 350g body wt., males age 10 weeks) bred at Biorex 
Laboratories were used. The colony was established from an 
SPF V/istar strain in 1970. The animals were housed in wire 
mesh cages. Mice and rats were originally supplied by Tuck 
& Son, Rayleigh, Essex, England and were fed on Dixons mouse 
and rat diet. Albino ferrets (1.3-2.6kg body wt., age 9-15 
months) were supplied by A.S. Roe, Little Fakenham, Nr.
Thetford, Norfolk, England. The animals were housed in wooden 
cages with straw bedding and fed raw meat, bread and milk.
Male Beagle dogs (10.8-12.3kg body wt., age 10-14 years) were 
supplied by Miss Heasmen Kennels, Denver Lodge, Nazeing,
Waltham Abbey, Essex, England. The animals were housed in 
dog pens with sawdust bedding and fed Spratts complete dog 
diet.
2.2.4 General
Pentobarbitone sodium (Nembutal, veterinary) was supplied 
by Abbott Labs., Queenborough, Kent, England. The following 
materials were purchased: liquid cover glass (Trycolac, Aerosol
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Marketing Co. Ltd., London, England); scotch 8lO pressure 
sensitive tape (Herts Packaging Co. Ltd., St. Albans, England); 
X-ray film (Kodirex, Kodak Ltd., Kernel Hempstead, England); 
polyethylene cannula tubing (Portex, Arnold R. Horwell, London, 
England); thin layer chromatography plates (Merck type 5755, 
Anderman and Co. Ltd., East Molesey, England); solid carbon 
dioxide pellets (Cardice, Distillers Ltd., Reigate, England); 
Dixons mouse and rat diet (type FFG(M) with added vitamins, 
Dixons Ltd., Ware, England); Spratts complete dog diet (Spratts 
Patent Ltd., Barking, England); heparinised tubes (Gelman 
Hawksley Ltd., Lancing, England); rubber catheters (Down 
Bros., Mitcham, England); disposable syringes and hypodermic 
needles (Gillette Surgical, Isleworth, England).
2.2.5 Determination of radioactivity
Radioactivity measurements were made using a Packard 5520 
liquid scintillation counter. Samples were counted in Brays 
scintillant plus Cab-o-sil (2,5-diphenyloxazole (20g),
1.4-di-2-(4-methyl-5-phenyloxazolyl) benzene (Ig), naphthalene 
(500g), methanol (500ml), 1,2-ethanediol (100ml), Cab-o-sil
(1 bag) and 1,4-dioxan to a final volume of 5 1) or 
Triton-toluene scintillant (2,5-diphenyloxazole (25g),
1 .4-di-2-(4-methyl-5-phenyloxazolyl) benzene (1.5g), toluene
(5 1) and Triton X-100 (2.5 1)) in 10ml aliquots using glass or 
plastic vials. All samples were counted for a minimum of 10,000 
counts or 100 minutes. Counting efficiencies were calculated 
using the external standard ratio method.
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2.2.6 Preparation of ^H-bifluranol for animal studies
The H-bifluranol was chromatographed on thin layer 
chromatography plates in the solvent system <C4o° petrol/ether (1/1) 
The material was visualised on the plate with ultra violet light 
and eluted from the silica with ethanol. This purification 
immediately prior to use was found to be necessary owing to 
radiochemical decomposition on storage. For the mouse, rat 
and ferret studies and the dog biliary excretion the bibenzyl 
was dissolved in propylene glycol or propylene glycol/saline 
(1/1). Unlabelled bifluranol was added where necessary to 
obtain the appropriate dose levels. The maximum volumes 
administered were 0.1ml (mouse), 0.2ml (rat), 0.4ml (ferret)
3
or 1ml (dog). For the other dog studies the H-bibenzyl was 
adsorbed onto starch from a small volume of ethanol (0.05ml) 
and the starch administered in a gelatin capsule.
2.2.7 Animal procedures
A metal needle with a small ball end was used for oral 
administration directly into the stomachs of mice and rats; 
intravenous administration was via the tail vein. Oral 
administration to conscious ferrets was performed by placing 
the drug solution onto the back of the tongue and allowing the » 
animal to swallow; anaesthetised animals were dosed by inserting 
a rubber catheter down the oesophagus into the stomach.
Intravenous dosing of ferrets was via the jugular vein under 
ether anaesthesia. Oral administration to conscious dogs was
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performed by placing the gelatin capsule on the bacK of the 
tongue and inducing the animal to swallow with water; 
anaesthetised dogs received the drug via a rubber catheter 
inserted down the oesophagus into the stomach. Blood samples 
were collected in heparinised tubes from the tail (rats), 
foot pads (ferret) or femoral vein (dogs). Bile cannulations 
under Nembutal anaesthesia (4o-45mg/kg in rat, 30-35mg/kg in 
ferrets and dogs) were performed, following a dorsal midline 
incision to expose the liver and upper intestinal tract, by 
insertion of a polyethylene cannula into the bile duct towards 
the liver.
2.2.8 Preparation of samples for radioactivity determination
Tissue samples were weighed and refluxed with alcoholic 
4c^ KOH. Aliquots of the solubilised material (0.5ml) were 
decolourised with 30?éw/v H2O2 (0-3ml) and neutralised with 
conc. HCl (0.2ml) prior to counting. Faeces samples were 
extracted with cold methanol for four days and then refluxed 
with alcoholic KOH; Aliquots of the solubilised material
(0.1ml) were neutralised with conc. HCl (0.02ml) and the volume 
adjusted to Irai with water prior to counting. Blood samples (0.05 
or 0.1ml) were solubilised in Hyamihe 10-X hydroxide (0.5ml), 
decolourised with 30%w/v H^O^ (0.3ml) and neutralised with 
2.5M HCl (0.1ml) prior to counting. Magnesium perchlorate 
used to trap expired water from metabolic studies was dissolved 
in water (20ml). Aliquots of urine (Irai), expired water (1ml) 
and bile (0.01ml) were counted directly.
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2.2.9 ■ Whole body autoradiography
^H-Bifluranol (2mg/kg,l.lffiCi) was administered orally or 
intravenously to male, female and pregnant mice, which were then 
sacrificed after various time intervals under ether anaesthesia 
by immersion in Cardiee/hexane at -70°C. The tail, limbs and 
ears were removed, the animals shaved, embedded and frozen 
in 5% aq. acacia so that lateral sections could be obtained. The 
animal blocks were sectioned using a Slee whole body freezing 
microtome. Of quadruplicate sections (30p) on pressure sensitive 
tape, taken at levels to demonstrate as many organs and tissues 
as possible, 3 were dried in the microtome cabinet for 3 days 
and the fourth stained by the technique of Farebrother and 
Woods (1975)' The section was thawed, air dried until the 
surface became opaque, fixed by flotation on 4% formol saline 
(3 min.) and stained with Harris’s haematoxylin (2 min.). The 
section was blued under tap water (10 sec.), cleared by 
flotation on glycerol (13 sec.), drained, dried between filter 
papers, sprayed with liquid cover glass and stored in a plastic 
bag. Freeze dried sections were exposed to X-ray film at 4°C 
and the autoradiograms examined for radioactivity distribution 
after 1,3 or 6 months.
2.2.10 Tissue radioactivity levels
^H-Bifluranol (60pg/kg,7“9mCi) was administered orally to 
5 male ferrets which were then sacrificed after various time 
intervals by ether anaesthesia and selected tissue samples
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X
removed. The H-content of the tissues was calculated.
2.2.11 96 hour excretion
^H-Bifluranol was administered orally to 3 male (200)ig/kg, 
246pCi) and 3 female (200)ig/kg,l84pCi) rats, 3 male ferrets 
(60pg/kg,490pCi) and 3 male dogs (30pg/kg,70-76mCi). All 
animals were housed individually in cages designed to allow 
separate collection of urine and faeces, which were taken every 
24 hours for 4 days. Expired water vapour from rats and ferrets 
was trapped in magnesium perchlorate. The recovery of 
administered in the excretory pathways was calculated.
2.2.12 Blood levels
' 5 H-Bifluranol was administered orally to o male rats 
(200pg/kg,lmCi), 3 male ferrets (60pg/kg,8 .4-10.6mCi) and 3 
male dogs (30pg/kg,70-76mCi); a further 6 male rats and 3 male 
ferrets received similar doses of the bibenzyl intravenously. 
Blood samples were taken for radioactivity determinations at 
various time intervals up to 98 hours (rat and ferret) or 6 
hours (dog) and the blood levels of the bibenzyl calculated 
from the specific activity of the dose,
2 .2 . 1 3 Biliary excretion
X
H-Bifluranol was administered to biliary cannulated rats 
(200pg/kg,2mg/kg or 20mg/kg,lmCi, orally or intravenously).
35
ferrets (60/ig/kg,0.8-1.05mCi, orally) and dogs (50}ig/kg,70-78mCi,
orally). Bile was collected for 4 hours (rat, intravenous),
6 hours (dog), 8 hours (ferret) or up to 72 hours (rat, oral). In
addition ^H-bifluranol (200rag/kg,3mC) was administered orally to
a biliary cannulated rat and bile collected for 34 hours to
provide material for mass spectrometry (section 4.2.3)•
Anaesthesia was maintained during the collection period with
further parenteral injections of Nembutal except in orally dosed
rats, which were allowed to regain consciousness and then
maintained in individual cages with free access to food and
water. At the end of the collection period any urine was
removed from the bladder and any bile from the gall bladder of
3the ferret and dog. The recovery of administered H was calculated
2.2.14 Enterohepatic circulation
Following■biliary cannulation the stomach was ligated at
the pylorus and a radioactive bile sample injected intraduodenally.
2 male rats received bile (30pCi,0.3ml) from a biliary
3cannulated rat which had previously received H-bifluranol 
orally (200pg/kg,ImCi) and 2 male ferrets bile (80/iCi,lml) 
from a biliary cannulated ferret which had previously received 
^H-bifluranol orally ( 6 0 p ^ k g , 1.03mCi). Bile was collected for 
8 hours, gall bladder bile removed from the ferrets and the
X
recovery of administered H calculated.
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2.3 RESULTS
2,3.1 Whole body autoradiography
Typical autoradiograms are presented in Figures 2.2 (male),
2.3 (female) and 2.4 (pregnant), the distribution of in males 
and females being similar in the common organs and tissues. Rapid 
localisation of the majority of %  to the liver and intestinal 
lumen was seen after oral or intravenous administration.
Following oral administration the main site of uptake outside 
the gastrointestinal lumen was the liver, with much lower levels 
in the kidney and bladden and a short term localisation of H in 
body fat. The testes and uterus showed a low transient 
accumulation of for up to 6 hours. Tissue levels were 
otherwise low, the highest systemic levels being reached after 
2 hours. The majority of had cleared the body after 24 hours, 
except for the intestinal lumen, liver and kidneys. No 
radioactivity was detected at 96 hours. In pregnant mice H was 
not detected in foetal tissues at 1 hour, but was present after 
4 hours, with accumulating in the liver and intestinal lumen. 
Foetal levels had fallen at 8 hours, and at 24 hours the mother 
had littered and the newborn mice showed a similar distribution 
to that observed in utero,
3 ■
Following intravenous administration the main site of H
' ' ■ . 3
uptake after 10 min. was the liver. subsequently rapidly
accumulated in the liver and intestinal lumen. Some retention of
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Fleure 2.2 Whole body autoradioerams of male mice following
intravenous administration of ^H-bifluranol
(2mg/kg. 1.1 mCi)
subcutaneous fat adrenal
kidney \ lung
brain
testis
in t e B tinal,.,,-^ '^  
lumen
: a t
liver
1 hour
liverfaecal pellets
l6 hours
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Figure 2.3 Whole body autoradiograms of female mice following
oral administration of ^H-bifluranol (2mg/kg, l.lmCi)
brain lung adrenal subcutaneous fat
y \  kidney \
. /
liver j intestinal lumen 
stomach
6 hours
‘uterus 
bladder
intestinal lumen
liver
24 hours
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Figure 2.4 Whole body autoradiograms of pregnant mice following
administration of ^H-bifluranol (2mg/kg, l.lmCil
liver
foetus intestinal lumen
1 hour# intravenous
liver
intestinal lumen
/
%
foetus
foetal intestines
4o
by the lungs and kidney was observed and transient localisation 
in body fat, testes and uterus also occurred. After 24 hours the 
majority of had cleared the body. The main sites of 
localisation of the remaining activity were the liver and 
intestinal lumen, with traces also present in the kidneys, lungs 
and bladder. These levels subsequently fell until only traces 
were present in the liver and lungs at 96 hours. readily
crossed the placental barrier and foetal levels were similar to 
those of the mother or marginally higher. At 1 hour a uniform 
distribution of was observed in the foetal tissues, but by 8 
hours localisation in the liver and intestinal lumen was observed. 
Traces of radioactivity were still present at 24 hours, although 
tissue levels,with the exceptions of the liver and intestinal 
tract, had fallen in line with those of the mother.
2 .3 . 2  Tissue radioactivity levels in ferret
Tissue levels (Table 2.1) were highest 30 min. after drug
3
administration, with the majority of H present in the
gastrointestinal tract and liver. Some uptake by the kidney and
3
lungs was also observed. Most of the H had cleared the tissues 
after 24 hours and only traces remained at 96 hours.
2.3*3 96 hour excretion
recovery (Table 2.2} was quantitative in the species 
studied, within the limits of the methodology. The major excretory 
pathway was the faeces, with only small quantities recovered in
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the urine of the 3 -species» Only traces:' (0*1%) of volatile
were found in the expired air from the rat and none with the 
ferret. No significant differences were observed in the 
excretory pattern for male and female rats, although recovery 
was slightly low in the latter.
2.3.4. Blood levels
a) Rat
3 ■ _
After intravenous administration, blood E levels (Figure 
2.5) fell rapidly with a t^ value of 45 min; this was followed 
by a much slower decline with a t^ value of 65 hours. The 
theoretical maximum blood level after intravenous administration 
was of the order of 3000ng/ml blood, compared with a value of 
550ng/ml recorded at the first blood sampling ( 15 min).
Following oral administration blood levels were falling
between 1 5 -6 0 min. with a t)é oi 43 min. Blood levels showed a
small rise after 1 hour, followed by a slow decline with a ty^
’ 3of 68 hours. Total b l o o d l e v e l s  never exceeded 1% of the 
administered oral dose at any time»
b) Ferret
• ' 3
Following intravenous administration, blood E levels 
(Figure 2.6) fell rapidly with a ty^  of 86 min; this was 
followed by a much slower decline after 6 hours, with a ty^ of
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Figure 2 q  Blood H levels in rat following oral 
or intravenous administration of
1000
H-bifluranol (200ng/kg)
intravenous administration
oral administration
"j* — standard error of the mean(n=6)
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63 hours. The theoretical maximum blood level after intravenous 
administration was of the order of lOOOng/ml blood compared with 
a value of 58ng/ml at the first blood sampling (10 min,).
Following oral administration blood levels reached a maximum 
at l8 min. and then fell rapidly with a t)é of 8o min; this was 
followed by a slow decline to reach very low levels, similar to 
those following intravenous administration between 24-96 hours.
Total blood levels never exceeded 3% of the administered oral 
dose at any time.
c) Dog
Blood levels (Figure 2.7) reached a maximum 116-3 hours 
after oral administration and fell slowly to 6 hours. Total blood 
levels never exceeded 1% of the administered oral dose at any time
2 .3 .5  Biliary excretion
recovery in the bile of the 3 species studied (Table 2.3)
was high following oral administration. Less than 3% was
recovered in the urine of these animals. In the single rat
■ 3
receiving 200mg/kg bifluranol 39% of administered H was 
recovered in the bile up to 54 hours, when the animal chewed 
through the cannula. The majority of administered was 
recovered in rat bile following intravenous, administration; 
less than 19  ^was recovered in the urine.
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Figure 2.7 Blood levels in do% following oral
administration of ^H-bifluranol (50PK/kR)
"y - standard error of the 
mean(n=3)
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■    -
2.3.6 Enterohepatlc circulation
' ' ' ' ' - - .  ^  ^ . I
Following intraduoderml adMnistration of biliary from animals
which had previously received ^E-biflnranol (rat 200ug/kg, ferret 60ug/kg), 
5
H recovery over 8 hours was 779^  (73^ and 81^) in rat bile and 19g$
(l8^ and 19fo) in ferret bile.
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2.4 DISCUSSION
5Autoradiographic and tissue- H data indicate that the 
distribution of bifluranol is similar in the mouse, ferret, 
and, in addition, rat (A.P. Gilbert, personal communication).
The major sites of accumulation are the liver and
gastrointestinal lumen following oral or intravenous administration.
The faeces is the major excretory pathway, with absorbed drug
being accumulated in the liver and excreted in the bile. The
small quantities of found in the kidney and urinary bladder
indicate the urine is a minor excretory pathway. The uptake of
by the testes and uterus may be associated with the endocrine
3properties of bifluranol. Very low H levels are present in the
animals after 96 hours indicating that a single dose is substantiallyj
eliminated from the body in this time. The disposition and 
3elimination of H in male and female mice is similar, indicating 
that there are no sex differences in the distribution of the 
compound by this species. Pregnant mice are capable of
5
rapidly excreting the drug and the distribution of the H found
3
in the foetus is similar to the adult. The presence of H in 
the foetal intestinal lumen indicates some biliary excretion of 
the bibenzyl by the foetus Occurs. .
3Blood H levels in rat, ferret and dog are low at all times 
following oral administration of bifluranol. In the rat and 
ferret the data indicate' a rapid initial uptake of drug by the 
body tissues, probably mainly by the liver. The similarity of 
the initial half life values following oral or intravenous
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administration implies a rapid oral absorption of the bibenzyl
3such that subsequent removal of H from the blood occurs at a 
similar rate to that of the intravenously administered drug. 
Following intravenous administration the very rapid initial fall 
in blood H levels from the theoretical maximum value was not 
measured; however the data does indicate an extremely rapid 
initial half life for the drug. The fall of blood levels 
to low values after 24 hours in the ferret indicates that final 
elimination of the bibenzyl is similar for both routes of 
administration. In view of the traces of volatile in the 
expired air of the rat it is possible that some of the blood 
measured is due to this aspect is more fully examined
in chapter 3«
The 96 hour excretion of bifluranol is similar in the rat,
ferret and dog, the major route of elimination being the faeces
with small amounts present in the urine. No sex differences
were observed in the rat and these results agree well with the
autoradiographic data in mice. The high biliary excretion
3
indicates that the low blood H levels and high faecal
elimination following oral administration are not a result of
poor drug absorption; the low blood levels of drug are more
likely to arise from rapid uptaKe by the liver and rapid biliary
excretion, as observed with intravenously administered drug. The
ability of the liver to readily eliminate bifluranol is
3
illustrated in the rat where the similar recovery of H in the 
bile over the dose range 0.2'-20mg/kg indicates the liver has 
not been saturated. The more extensive enterohepatic
52
circulation of in the rat, compared to the ferret, probably
accounts for the slower rate of faecal elimination in the rat
observed in the 96 hour excretion study.
Thus the distribution of bifluranol is similar in the four 
species studied, the pattern being one of rapid absorption, low 
blood levels due to extensive hepatic uptake and biliary excretion, 
with predominantly faecal elimination of a single dose within 
96 hours. This pattern is essentially similar to that of 
diethylstilboestrol in rodents (see section 1.2), the only notable 
difference being that mouse autoradiography shows 
diethylstilboestrol is localised in the’ adrenals, whereas 
bifluranol is not (Bengtsson and Ullberg, 1963).
5)
CHAPTER 3 
METABOLISM OF BIFLURANOL
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3.1.1 Metabolic reactions of drugs
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3.1 INTRODUCTION
3 .1 .1 Metabolic reactions of drugs .
Drugs are metabolised primarily either in the tissues which 
the compound first encounters in the body, such as the lung or 
gastrointestinal tract, or in the tissues concerned with 
elimination, such as liver and kidney. Metabolic alterations 
are classified either as Phase 1 reactions, which include 
oxidation, reduction, hydrolysis and degradation reactions, 
or Phase 2 reactions, which include glucuronidation, sulphation 
and amino acid conjugations and also méthylation, acétylation 
and acylation reactions. The major metabolic alteration to both 
diethylstilboestrol and phenol is Phase 2 glucuronidation and, 
for phenol, sulphation (Capel, et al, .1972; Fischer, et al, 1966), 
although, as seen in section 1.2, Phase 1 oxidation also occurs 
to a significant extent with diethylstilboestrol. ■
Phase 1 oxidation of most drugs is catalysed by a cytochrome 
p -4 5 0 dependent microsomal mixed function oxidase which is 
located primarily in the smooth endoplasmic reticulum and requires 
NADPH and oxygen (Figure 3*i) (Holtzraan, et al, 1968). The major 
site for these reactions is the liver (Rammer, 1976), although 
different types of cytochrome P-430, with different substrate 
specificities, have been noted in several tissues (Orrenius, 1976)
Conjugation with glucuronic acid (Figure 3.2) involves the 
reaction of a high energy intermediate, UDPGA, with a suitable
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Fleure 3.1 Mechanism of cytochrome P-4^0 drug
oxidation (Holtzman, et al, 1968)
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acceptor group on the drug. The enzyme activity is located in 
the microsomes and this proximity to the mixed function oxidases
may be important in the efficient elimination of drugs (Vainio,
1976). Different forms of the enzyme have been reported, although 
at present it is not clear whether there are single or multiple 
enzyme forms (Dutton and Burchell, 1977). Sulphate conjugation
of phenols and phenolic steroids (Figure 3«2) involves the reaction 
of the high energy intermediate PAPS with the phenolic hydroxyl.
The enzyme activity is localised in the soluble cell fraction and 
may also be due to more than one enzyme (Dodgson, 1977).
Whilst the liver is the major source of the enzymes involved 
in these reactions, other sites are also capable of metabolising 
drugs to a considerable extent. The intestinal tract glueuronylates 
diethylstilboestrol (Fischer and Millburn, 1970), whilst phenol 
is conjugated with both glucuronic acid and sulphate (Powell, 
et al, 1974).
3 .1 .2  Factors affecting metabolism of drugs
One of the most important considerations in studying drug 
metabolism is the species of animal in which the studies are 
carried out. Despite the large potential for variation there is 
remarkably little difference in the types of reaction performed 
by various mammalian species and with few exceptions the 
differences are largely of degree only and can be traced to 
variations in the enzymes involved in metabolism (Hirom, et al,
1977).
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The cat produces few glucuronide conjugates and instead 
relies on sulphate and amino acid conjugation. The affinity of 
1-naphthol for glucuronyltransferase is considerably lower in the 
cat than the rat, whilst the affinity for the sulphotransferase
is much higher in the cat, so that this partial genetic deficiency 
in glucuronidation in the cat is compensated for by a more 
efficient system of sulphate conjugation (Capel, et al, 1974b: 
Hirom, et al, 1977).
Species differences in the conjugation of phenol show a 
wide degree of variability in glueuronide and sulphate 
conjugation in animals capable of producing both conjugates 
and oxidative metabolism also varies considerably (Capel, et al, 
1972). The enzyme systems involved in conjugation are affected 
by substrate concentration and other factors and this alters the 
relative importance of various pathways at different dose levels. 
Thus phenol at $Omg/kg in rabbits produces almost equal amounts of 
glucuronide and sulphate conjugates, whilst at 250mg/kg sulphate 
conjugation is only 19%, with glucuronide formation correspondingly 
increased. This may be due to glucuronide conjugation being 
proportional to the tissue concentration of phenol whereas 
sulphate conjugation is limited by sulphate availability 
(Williams, 1959).
The dose level of a drug has been shown to be critical in 
producing certain types of toxicity. The severity of hepatic 
necrosis produced by acetaminophen (Mitchell and Jollows, 1975) and 
bromobenzene (Reid, et al, 1975) was related to the extent of
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covalent binding of drug to the liver. The percentage of a given 
drug binding to the liver rose marginally with increasing amounts 
administered until a threshold was reached when extensive tissue 
binding and necrosis occurred. This threshold phenomenon was 
correlated with depletion of hepatic glutathione, which was 
protecting the cell by binding to the cytotoxic epoxide metabolites 
arising from oxidative metabolism. Thus, with drugs which undergo 
oxidative metabolism, the extent of oxidation and dose level are 
of considerable importance in relation to metabolism mediated 
toxicity.
Many other factors also exert effects on the metabolism of 
drugs. At birth, animals generally have little ability to 
metabolise drugs, although the enzyme systems develop soon after 
birth (Kato, et al, 1964; Basu, et al, 1971; Fischer and 
Weissinger, 1972; Klinger, et al, 1975; loannides and Parke, 1975)* 
Several of the reactions of drug metabolism also occur in the 
metabolism or deactivation of endogenous compounds such as lipids 
and steroids (Gillette, et al, 1969), from which it may be inferred 
that the nutritional and hormonal status of the animal will also 
affect metabolism. However, whilst the oxidation reactions may be
I
similar, hepatic and extrahepatic cytochrome p450 s and p448 have 
been found to have different specificities and induction 
characteristics for different substrates. Thus phenobarbitone 
only induces liver cytochrome P450, intestinal and lung p450 only 
metabolise carcinogens and kidney p450 only metabolises fatty 
acids (Orrenius, 1976), Furthermore, the corticosteroid hormones 
have been implicated in the regulation of microsomal drug
6o
metabolising enzymes in response to alterations in diet (Parke, 
1971). Thus it can be seen that drug metabolism is dependent on 
several factors which are closely interrelated with many other 
functions in the body.
3 .1 .5  Experimental approach
Samples of faeces, bile and urine from the animals v/hich 
received^H-bifluranol in the studies detailed in Chapter 2 have 
been analysed by à variety of techniques to determine the 
metabolic fate of bifluranol. Methodology for the separation 
of the metabolic products involved chromatographic procedures 
and where possible comparison with authentic compounds. Specific 
enzymic hydrolyses were used to characterise the conjugates of 
bifluranol.
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3.2 EXPERIMENTAL
3.2.1 Materials
^H-biflurariol was the material described in sections 2.2.2 and
2.2.6. The following materials were purchased; general chemicals 
and glucuronidase low in arylsulphatase (B.D.H. Chemicals,
Poole, Dorset, England); arylsulphatase from limpets (Type III), 
potato acid phosphatase, calf intestinal mucosa alkaline 
phosphatase, UDPGA transferase (Type II from rabbits) and UDPGA 
(Sigma Chemical Co. Ltd., Kingston, Surrey, England);
1,4-saccharolactone (Calbiochem Ltd., Bishops Stortford, Herts., 
England); solid carbon dioxide (Distillers Ltd. , Reigate, England) 
X-ray film (Kodirex, Kodan: Ltd., Hemel Hempstead, England); thin 
layer chromatography plates (Merck Type 5755) and preparative 
layer chromatography plates (Merck Type 5717) (Anderman and Co. 
Ltd., East Molesey, England). Brays and Triton-toluene 
scintillants were prepared as described previously (section 2 .2.5 )*
3.2.2 Administration to animals
Details of the animals used, dose levels of bifluranol and 
the methods of collection of faeces, urine and bile samples are 
detailed in sections 2 .2 .1 1 and 2 .2 .1 3.
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3.2.3 Thin layer chromatography
Aliquots (3pl) of the material to be examined were 
chromatographed on silica gel 6OF 254 plates (0.2mm) in one or 
more of the following solvent systems:
a) n-butanol/acetic acid/water (4/1/1)
b) n-propanol/ammonia (s.g. 0 .8 8) (7/3)
c) n-butanol/1 .5% aq. ammonium carbonate (2/ 1 )
d) <40^ petrol/ether/ethanol (8/ 8/ 1 )
A -bifluranol standard was chromatographed in all t.l.c. work.
Each plate was divided into 20 0.5cm segments for radioassay 
after development over a 10cm distance. The silica was scraped 
into scintillation vials containing Bray’s scintillant mixture 
plus Cab-o-sil (10ml) or Triton-toluene scintillant (10ml) plus 
water (1ml) and the content determined (section 2 .2 .5 ) *
Autoradiograms were obtained by exposing the plate to X-ray
3film for up to 21 days for samples containing more than l^Ci H. 
Samples containing less than IpCi were impregnated with 10%
2 ,5-diphenyloxazole in benzene and exposed to X-ray film at 
-70^C for up to 21 days; this procedure gave about a 30—fold 
increase in sensitivity, as reported previously (Rogers, 1973). 
Radioassay and autoradiography were used in combination to make 
a quantitative assessment of individual metabolites.
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3.2.4 Procedures for hydrolysis of conjugates
a) p_glucuronidase
Aqueous samples (0.1ml) in 0.2M acetate pH3«0 containing 
0.01M sodium fluoride (sulphatase inhibitor) were incubated with 
10,000 Fishman units' of ^-glucuronidase at 37°C for 6 hours. 
Control samples also contained O.OIM 1,4 saccharolactone 
(]^-glucuronidase inhibitor).
b) Sulphatase
Aqueous samples (0.1ml) in O.IM acetate 0.004m sodium 
chloride pH3.0 containing O.OIM 1,4 saccharolactone were 
incubated with arylsulphatase (0 .1  units) at 37^C for 6 hours. 
Control samples also contained O.OIM sodium fluoride.
c) p-glucuronidase and sulphatase
Aqueous samples (0.1ml) in 0.2M acetate 0.004m sodium 
chloride pE3 .0  were hydrolysed as above without the enzyme 
inhibitors 1,4 saccharolactone and fluoride. Sequential and 
combination hydrolyses were used,
d) Phosphatase
Aqueous samples (0.1ml) in 0.2M acetate pH5«0 or 0.2M tris 
pH9»5 were incubated with acid or alkaline phosphatase (1 unit)
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respectively at 37^C for 6 hours
e) Acid
Aqueous samples (0.1ml) in 2M HCl were heated (80-90°C) 
for 15 minutes and cooled.
5 .2 .5  Analysis of biological samples
a) Bile
Pooled samples from the biliary excretion studies (section 
2.2.1 5) in rat (0 .2 ,2  and 20mg/kg oral (24 or 72h), intravenous (4h) 
and 200mg/kg oral (54h)), ferret (0 .06mg/kg oral (8h)) and dog 
(0 .05ni&/kg oral (6h)) were analysed before and after hydrolysis 
with ^-glucuronidase and/or sulphatase or acid by t.l.c. 
autoradiography (solvent systems a-d) and radioassay (solvent 
systems (a) and (d)). Ferret and dog bile samples were also 
analysed following hydrolysis with phosphatase.
Rat bile (200pg/kg oral) was chromatographed in solvent 
system (a) and the 4 components located by autoradiography 
were eluted from the silica with 5% aq. methanol. The 4 samples 
were hydrolysed with p-glucuronidase and/or sulphatase and 
examined by t.l.c. autoradiography (solvent systems a-d).
Ferret bile was chromatographed in solvent system (b), the 
major metabolite not found in rat bile (Metabolite 6 , section
6$
3 .5 -1 ) was located by autoradiography and eluted from the silica 
with 50% aq, methanol. Aqueous samples were examined by t.l.c. 
radioassay (solvent system (a)) before and following hydrolysis 
with p-glucuronidase, sulphatase or acid.
' 3 'Rat bile samples from animals receiving R-bifluranol 
(2Gmg/kg, oral and intravenous) and from untreated controls were 
chromatographed in solvent system (a), sprayed with 0 .2%
o'
naphthoresorcinol in acetone/9% H^POj^ (5/1), heated at 120 G for 
10 minutes and the position of blue bands (glucuronides) 
recorded (Partridge, 1948).
Biliary was recrystallised to constant specific activity 
with bifluranol following hydrolysis of conjugates with 
p-glucuronidase and acid. The content of bile (1ml) from
•Z
animals which had received '^H-bifluranol orally (rat 200pg/kg, 
ferret 60pg/kg and dog 50pg/kg, section 2 .2 .1 3) was determined 
and bifluranol (50mg) added. The samples were hydrolysed in 
0.2M acetate pH 5-0 at 37°C for 16 hours with p-glucuronidase 
(10,000 Fishman units), acidified to 2M HCl, heated (80-90°C) 
for 30 minutes and cooled. The samples were extracted with ethyl 
acetate (3 X 5ml, ^  99% extraction), evaporated to dryness, 
redissolved in a minimum of ether and bifluranol recrystallised 
following addition of 40-60° petrol (10 vol.). The material was 
dried and the specific activity determined. Recrystallisation 
and specific activity determination was repeated three times.
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b) Urine
Samples from the 96 hour excretion studies in rat, ferret 
and dog (section 2.2.11) were chromatographed in solvent system
(a), analysed by t.l.c. radioassay and autoradiography and the 
metabolite patterns compared with those found in bile. In 
addition, urine removed directly from the bladder in the dog 
biliary excretion study (section 2.2.13) was examined by t.l.c. 
radioassay (solvent system (a)) and autoradiography in solvent 
systems a-c before and after p-glucuronidase or sulphatase 
hydrolysis.
%
Volatile H content of urine was determined by measuring 
the content of urine before and after drying. Rat urine samples 
were pooled, distilled, acidified (2M HCl) and aliquots of the 
distillate (1ml) counted before and after extraction with ethyl 
acetate ( 2 x 2  vol.).
c) Faeces
Methanolic extracts from the 96 hour excretion study (section
2.2.11) were chromatographed in solvent system (a), analysed by
5 't.l.c. radioassay and the- H distribution compared to that 
found in bile.
3.2.6 Synthesis of potassium bifluranol disulphate
The methods used for the syntheses of bifluranol sulphate
67
esters were based on similar syntheses for diethylstilboestrol 
(Barford, et al, 1977a). Chlorosulphonic acid (0.3ml) was added
. I ■
slowly to a stirred mixture of N,N -dimethylaniline (2.3ml) and 
carbon disulphide (3.2ml) at -3°C. After 5 minutes the mixture 
was allowed to reach room temperature and bifluranol (500mg) was 
added to the stirred mixture, which was left overnight. The 
solid was isolated by centrifugation, washed with ether (3 x 3ml) 
and the crude disulphate recrystallised from hot water (80°C) 
following neutralisation with 30?o KOH. The crude product 
was purified by chromatography on preparative t.l.c. plates 
(2mm) in solvent system (a). The material was eluted from the 
silica with acetone/water (3/2, 3 x 20ml), and dried vacuo 
at 4o°C. The solid was dissolved in hot water (8o°C), 
neutralised with 50% KOH and crystallised. The material was 
recrystallised three times from water. The product (120mg) 
gave analysis values for K"^  and SO^ in agreement with the 
structure of potassium bifluranol disulphate (Found: K, 15.5%i 
SO^", 55.8%. C^yH^^OgFgSgK^ requires K, l4.8%, S0^“ , 56.4%).
The material was chromatographed in solvent systems a-d 
for comparison with metabolites of bifluranol from vivo 
studies,
3 .2 .7  Synthesis of potassium bifluranol monosulphate
Bifluranol (440mg) was dissolved in dry pyridine (7ml) and 
the mixture cooled to 0°C. Chlorosulphonic acid (0.12ral) was added 
slowly to the stirred mixture, which was stirred for a further
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30 minutes and left overnight at room temperature. The solution
was diluted with ether (13ml) an d  the precipitate, which turned
to a gum on centrifuging, removed. After washing with ether
(2 X 20ml) the material was neutralised with 20% KOH and the crude
product was purified by chromatography on preparative t.l.c.
plates (2mm) in solvent system (a). The material was eluted
from the silica with acetone/water (1/1, 3 x 20ml) and dried ^
vacuo at 4o^C. The solid was dissolved in hot water (8o C),
neutralised with IM KOH and crystallised. The material was
recrystallised twice from water. The product (32mg) gave
analysis values for K*^  and S0^~ in agreement with the structure
of potassium bifluranol monosulphate (Found: K, 10.1%; SO^ , 22.9%.
■ 2-
^17^17^5^2^^ requires K, 9-5%; 80^  ^ , 23.496).
The material was chromatographed in solvent systems a-d 
- — " — “ “ —
3.2.8 Enzymic synthesis of bifluranol monoglucuronide
^H-Bifluranol (120pg, 50pCi) in propylene glycol (0.1ml) was 
incubated with 0.5M tris/0.15M MgCl^ pH8.0 (0.2ml), UDPGA (0,2$mg 
in 1.15% KCl (0.25ml)) and UDPGA transferase (48rag in 2.4ml water) 
under nitrogen at 37 C for 30 minutes. The mixture was acidified 
with 2M HCl (0.5ml) and the monoglucuronide and unchanged 
bifluranol extracted into ethyl acetate (2-x 5ml). The t.l.c. 
characteristics before and after ^-glucuronidase hydrolysis in 
solvent systems a-d were compared to those of the metabolites of
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bifluranol from ^  vivo studies. Due to the nature of the 
synthesis and the small amounts of monoglucuronide formed no 
chemical analysis of bifluranol monoglucuronide was possible
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5-5 RESULTS
3 .3 .1  Biliary radioactivity
Several metabolites were found in the bile of animals dosed 
with bifluranol. These have been preliminarily identified on 
the basis of their t.l.c. characteristics assessed by 
autoradiography and radioassay before and following various 
hydrolytic procedures. The Ef values of the metabolites of 
bifluranol (Table 3*1) and the percentage of each metabolite 
in bile collected (Table 3.2) are summarised. Because of the 
manner in which the radioassays were performed and animal 
variation the accuracy of the individual percentage values for 
each metabolite in bile varies by up to - 23% of the values quoted. 
Autoradiograms which were overexposed indicated that traces 
of other metabolites were present in the samples analysed.
However, radioassay showed that none of these minor components 
contributed more than 0.5% of the radioactivity present in the 
sample and these trace metabolites have not been examined further.
Metabolite 1 (Bifluranol monosulphate) was not labile to 
sulphatase or ^-glucuronidase but was labile to acid hydrolysis 
to give bifluranol. Synthetic bifluranol monosulphate had 
similar t.l.c. properties and metabolite 1 was designated 
bifluranol monosulphate.
Metabolite 2 (bifluranol monoglucuronide) was labile to 
p-glucuronidase to give bifluranol, gave a positive glucuronide
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Table 3.1 Rf values for bifluranol and metabolites
Component Rf in solvent system
a b c d
bifluranol 0.85 0 .57 0.85 0 .55
bifluranol 
monosulphate
0.65 0.55 0.81 0
bifluranol 
disulphate
0.43 0.44 0.54 0
bifluranol
monoglucuronide
0.48 0. 26 0.17 0
bifluranol
diglurunonide
0.22 0.10 0.04 0
bifluranol
glucuronide
sulphate
0.31 0.26 0.09 0
bifluranol
glucuronide
phosphate
0.33 0 .18 0.11 0
metabolite 7 
glucuronide
0.43 0.22 0.13 . 0
metabolite 7 - 0.84 0.48 0.84 0 .25
solvent systems! (a) n--butanol/acetic acid/water (4/1/1)
(b) n-propanol/amraonia (s.g. 0.88)(7/3).
(c) n~butanol/1.5?o aq. ammonitim carbonate (2/l)
(d) ^40*^petrol/ether/ethanol (8/8/1)
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test with naphthoresorcinol and was not labile to sulphatase. 
Enzyraically synthesised bifluranol monoglucuronide had similar 
t.l.c. properties and metabolite 2 was designated bifluranol 
monoglucuronide.
Metabolite 3 (bifluranol disulphate) was not labile to 
p-glucuronidase, gave bifluranol monosulphate on sulphatase 
hydrolysis, bifluranol on acid hydrolysis and had similar t.l.c. 
properties to synthetic bifluranol disulphate. Metabolite 3 
was designated bifluranol disulphate.
Metabolite 4 (bifluranol diglucuronide) was labile to 
p-glucuronidase to give bifluranol, gave a positive glucuronide 
test with naphthoresorcinol and was not labile to sulphatase. 
Partial hydrolysis gave bifluranol monoglucuronide. Metabolite 
4 was designated bifluranol diglucuronide.
Metabolite 5 (bifluranol glucuronide sulphate) was labile 
to p-glucuronidase to give bifluranol monosulphate, to sulphatase 
to give bifluranol monoglucuronide and to p-glucuronidase and 
acid to give bifluranol. Naphthoresorcinol gave a positive 
glucuronide test. Metabolite 5 was designated bifluranol 
glucuronide sulphate.
Metabolite 6 (bifluranol glucuronide phosphate) was labile 
to ^-glucuronidase but not sulphatase or phosphatase whilst 
present in bile. Following t.l.c. isolation the material was 
labile to acid phosphatase to give bifluranol monoglucuronide
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and to p-glucuronidase and acid to give bifluranol. The material 
was not labile to sulphatase or alkaline phosphatase. Metabolite 
6 was tentatively identified as bifluranol glucuronide phosphate.
Metabolite 7 glucuronide was labile to ^-glucuronidase but 
not sulphatase to give metabolite ?i which was not bifluranol. 
This material is examined in detail in Chapter 4.
Following complete hydrolysis of rat, ferret and dog bile 
from animals receiving ^H-bifluranol and recrystallisation of 
the with bifluranol to constant specific activity the 
following values were obtained. The theoretical specific 
activities of bifluranol from rat, ferret and dog bile were 
0.93, 1.04 and 22.4pO/mg respectively. Values found, based on 
the mean of the last two recrystallisations, were 0.91pC/mg 
(98%), 1.07pC/mg (103%) and 22.4pC/mg (100%).
3*3.2 Urinary radioactivity
5
Urinary H following oral administration of bifluranol to
rat, ferret and dog had similar t.l.c. characteristics to the
metabolites found in the bile, as assessed by autoradiography
and radioassay (Table 3*3)• No H was lost on drying urine
samples from ferret ands dog. 30-35% of male and female rat 
3Urine H was lost on drying. Urinary excretion of orally 
administered bifluranol was 12% in male and 5% in female rats
3
(Table 2.2). The values for volatile H therefore represent
34% and 2% oxidation of bifluranol H in male and female rats
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Tabie 3.3 Percentage composition of faecal and urinary 
3H in rat, ferret and dog following oral
3administration of ''^H-bifluranol.
Component
preliminary determination of % composition 
of faecal and urinary
Rat
(200pg/ks, n=3) 
faeces urine
bifluranol + 
metabolite 7
bifluranol 
mono sulpha t e
bifluranol 
disulphate, 
monogluc ur oni d e 
and metabolite 7 
glucuronide
bifluranol
diglucuronide
bifluranol 
glucuronide 
sulphate + 
glucuronide 
phosphate
unidentified
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6
11
3k
11
trace
trace 32
Ferret
(60pg/kg, n=3) 
faeces urine
60
21
14
44
19
25
trace trace
trace
Dog
(50}ig/kg, n=3)
faeces urine
85 2 (trace)
19 (10)*
33 ( 20) *
14 (15)
trace 27 (50)*
5 (5 )*
% of dose 
examined
88 a 93 95 (<i)
trace = <2?*
• these values are from the biliary excretion in dogs (section 2,2.11)
* Percentage figures are based on t.i.e. radioassay following chromatography 
In n-butanol/acetic acid/water (4/1/1).
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3respectively, based on urine analysis alone. Volatile H 
distilled between 97--100°C and the aqueous was not extractable 
with ethyl acetate.
3 .3 .3 Faecal radioactivity
3
The bulk of H present in the faeces following oral
administration of bifluranol to rat, ferret and dog had t.l.c.
characteristics similar to those of bifluranol and bifluranol
monosulphate as determined by radioassay in solvent system (a)
3(Table 3 .3 )» Small amounts of H corresponding to other 
conjugates of bifluranol were also present.
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3.4 DISCUSSION
3From the examination of biliary H following administration 
of ^H-bifluranol to biliary cannulated animals it is apparent 
that bifluranol is not suitable for biliary excretion without
3
prior conjugation. However, faecal H consists predominantly of 
bifluranol, in spite of extensive absorption and excretion in 
the bile as conjugates. Enterohepatic circulation of bifluranol 
was observed.(chapter 2), especially in rat, and by analogy with 
diethylstilboestrol (Clark, et al, 1969; Fischer, et al, 1973) 
this requires hydrolysis of conjugates by bacterial enzymes before 
reabsorption of the free drug. However, if this hydrolysis occurs 
in the caecum or bowel reabsorptioh is poor and free drug appears 
in the faeces. Bacterial hydrolysis of bifluranol conjugates 
probably accounts for the high levels of bifluranol found in 
faecal samples.
*
The pattern of urinary metabolites of bifluranol as assessed 
by autoradiography and radioassay (Table 3*3) is similar to the 
pattern observed in bile. Whilst free bifluranol appears in urine 
samples of rat and ferret, only traces appear in dog urine and it 
is possible that this free drug arises from the breakdown of 
conjugates in the urine, since no precautions were taken to 
prevent bacterial contamination of samples.
Little Phase 1 metabolism of bifluranol is observed, the 
rat being the only species of the three studied to give any 
evidence of significant metabolism following a single dose. The
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rat is the only species to yield material not corresponding to 
bifluranol after total hydrolysis of biliary conjugates and even 
here the level of metabolism of 4% is low compared to the 30% 
oxidation reported for diethylstilboestrol (Metzler, 1975, 1976).
The lower amounts of metabolite 7 found in bile following 
intravenous as opposed to oral administration may mean that 
metabolism occurs in the gastrointestinal tract or that the 
glucuronide of metabolite 7 is less readily eliminated in bile. 
Metabolite 7, the only major Phase 1 metabolite found in these 
studies, is examined in detail in Chapter 4.
The major conjugation of bifluranol with glucuronic acid is 
not unexpected, although the extensive appearance of the double 
conjugate with sulphate is unusual, this phenomenon having only 
been observed to occur previously with oestriol in man (Stoa and 
Levitz, 1968) and diethylstilboestrol in guinea pig (Barford, et al, 
1977b). Glucuronide sulphate diconjugates of nitrocatechol, 
biphenyl, cyclohexylphenyl, oestrone and diethylstilboestrol in rat 
bile were only obtained following parenteral administration of 
the sulphate esters (Flynn, et al, I9 6 6: Hears e-, et al, 1969 ; 
Gatehouse, et al, 1972; Barford, et al, 1977a). The conjugation
of bifluranol in rat is examined in more detail in Chapter 5 .
. ■ ■
The appearance of a glucuronide phosphate diconjugate in 
ferret and dog bile is highly unusual and will require further 
confirmation by synthesis of bifluranol phosphate. The only 
other reported conjugation of a phenolic compound with phosphate 
was that of phenol in the cat (Capel, et al, 1974a).
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The presence of the glucuronide phosphate in ferret and dog 
bile and urine, but not in rat samples, and the oxidation of 
bifluranol by rat, but not ferret or dog, are the major species 
differences in the routes of metabolism of bifluranol. There is 
also a qualitative difference in the extent of double conjugate 
formation, ranging from 50% in rat to almost 100% in ferret, 
with the dog in an intermediate position. The ferret also 
differs from the rat in being able to excrete the disulphate 
conjugate of bifluranol in bile.
The percentage amounts of conjugates in rat bile at dose 
levels from 0.2-200mg/kg are similar and the absence of any 
increase in the amount of the Phase 1 metabolite, metabolite 7, 
suggests that the enzyme systems involved in production of the 
conjugates have not been saturated. The similarity in the 
percentage amounts of glucuronide sulphate over this range, and 
therefore the amount of sulphate conjugation, indicates that 
sulphate conjugation has not been limited by sulphate availability. 
Studies by Williams (1959) showed that a dose level increase of 
phenol from pOmg/kg (O.55cimol/kg) to 250mg/kg (2.66mmol/kg) was 
necessary to significantly reduce sulphate conjugation in rabbit, 
and this range is considerably higher than that of bifluranol in 
these studies (O.7~685p 3iol/kg).
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4.1 INTRODUCTION
In Chapter 3 bifluranol was shown to produce an 
unidentified glucuronide (metabolite 7) corresponding to 4%
of the biliary radioactivity following oral administration of
5 3H-bifluranol to rats. Volatile H was also detected in urine
samples from rat at a similar level (4% eliminated in 96h).
5
Since the H of bifluranol was shown to be stable in acid and 
alkali (section 2.2.2), the position of substitution in 
bifluranol is metabolically unstable in rat.
4.1.1 Oxidative metabolism
Diethylstilboestrol has been shown to undergo several 
oxidation reactions in rat (see Figure 1.3), including aromatic 
hydroxylation, the products being identified by mass spectrometry, 
It is reasonable to propose that similar aromatic hydroxylation 
would also occur with bifluranol.•
Oxidative metabolism of diethylstilboestrol has been shown 
to lead to binding to protein and DNA using ^  vitro systems 
(Krishna, et al, 1973; Blackburn, et al, 1976). This type of 
metabolism is consistent with the formation of a reactive 
epoxide or arene oxide intermediate (see Figure 1.3) which can 
bind to protein, DNA and glutathione. Studies with 
ethynyloestradiol have shown that 2 hydroxylation is the major 
pathway of oxidative metabolism (Bolt, et a l , 1973) and further 
studies using microsomal preparations have shown irreversible
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binding of metabolites of ethynyloestradiol to protein, with a 
reduction of this binding in the presence of glutathione (Kappus, 
et al, 1973; Bolt and Kappus, 1974). However, these authors 
propose quinone type intermediates as the reactive species 
involved in protein binding.
The liver has been studied as the major site of oxidative 
metabolism of diethylstilboestrol (Engel, et al, 1976) and 
ethynyloestradiol, but studies with diethylstilboestrol in 
ruminants have also shovm extensive degradation of the drug by 
intestinal contents (Aschbacher, 1976). This must be considered 
as a possible site of metabolism of bifluranol, especially in 
view of the lower amounts of metabolite 7 found in rat bile 
following intravenous as opposed to oral administration 
(Table 3.2).
4.1.2 Experimental approach
Metabolite 7 has been examined by mass spectrometry and the 
fragmentation pattern compared to authentic hydroxylated 
derivatives of bifluranol. Various systems in vitro were used to 
examine the oxidation of bifluranol in attempts to produce 
metabolite 7 and to examine whether microsomal oxidation of 
bifluranol leads to binding of the bibenzyl to protein and 
glutathione, as occurs with other aromatic structures.
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4.2 EXPERIMENTAL
4.2.1 Materials
3
H-bifluranol was the material described in sections 2.2.2 and
2.2.6. The following materials were purchased; general chemicals, 
nicotinamide, NADP, glucose-6-phosphate and G6p-dehydrogenase 
(from yeast) (B.D.H. Chemicals, Poole, Dorset, England); 
tyrosinase (Sigma Chemical Co. Ltd., Kingston, Surrey, England); 
X-ray film (Kodirex, Kodak Ltd., Hemel Hempstead, England); thin 
layer chromatography plates (Merck type 3735, Anderman and Co.
Ltd., East Molesey, England); trimethylchlorosilane (Phase 
Separations Ltd., Queensferry, Flintshire, England). Brays and 
Triton toluene scintillants were prepared as described previously 
(section 2.2.3). All solvents used in isolation of material for 
mass spectrometry were redistilled from Analar grade material as 
supplied.
, , ' , '
Erythro-3,3 -difluoro-4,4 ,3,3 -tetrahydroxy-o4.methyl-p6-
*
ethyl bibenzyl (dihydroxy bifluranol) and erythro-3,3 -difluoro-
4,4 ,3-trihydroxy-o<.-methyl-o<-ethyl bibenzyl (2 isomers of 
monohydroxy bifluranol) were synthesised by Dr. R.P. Chan at 
Biorex Laboratories, London, N1 2HB.
4.2.2 Administration to animals
3
Details of the biliary excretion of H-bifluranol (200mg/kg, 
oral) are given in sections 2.2.1 3 , 2.3.3, 3.2.3 and 3.3.1.
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4.2.3 Determination of radioactivity
Radioactivity measurements were, made as described previously 
(section 2.2.3)•
4.2.4 Thin layer chromatography
Samples were analysed by t.l.c. (section 3*2.3) using one or 
more of the following solvent systems;
d) <^40° petrol/ether/ethanol (8/8/1)
e) toluene/piperidine (3/2)
f) ethyl acetate/isopropanol/water (63/24/12)
These solvent systems had previously been shown to provide good 
separation of bibenzyl analogues of bifluranol.
4.2.3 Isolation of metabolite 7 for mass spectrometry
Bile from a rat which had received H-bifluranol (200mg/kg, 
oral) was acidified with 2.3M HCl (1ml) and extracted into ethyl 
acetate (3 x 10ml). The extracted glucuronide fraction was dried, 
reconstituted in 0.2M acetate buffer pH3*0 (3ml) and hydrolysed 
with p-glucuronidase (13,000 Fishman units) at 37°C for 8 hours. 
The sample was acidified with 2.3M HCl (1ml) and metabolite 7 
extracted into ethyl acetate (4 x 3®1)« The material was isolated 
by t.l.c. in solvent system (d), radioactivity corresponding 
to metabolite 7 located by radioassay and eluted from the silica 
with ethanol.
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Samples of the isolated metabolite 7 and authentic bifluranol 
were dried and derivatised for g.l.c, v/ith trimethylchlorosilane.
I
Samples (Ipl) were applied separately to a 5 column of 1% 0V17 on 
100-120 mesh Gas Chrom Q at l8o°C (N£ flow 50ml/min) in a Pye 
series 104 g.l.c. and retention times measured. A crude 
radiochromatogram of the metabolite 7 was obtained by placing 
scintillation vials containing magnesium perchlorate (0.3g) over . 
the jet outlet of the g.l.c. detector. The vials were changed every 
2 minutes, water (1ml) added to dissolve the magnesium perchlorate 
and the samples counted in Triton toluene scintillant (10ml).
Methyl derivatives of metabolite 7 (circa 50pg)^-bifluranol 
and mono- and di-hydroxy bifluranol were prepared by reaction 
with ethereal diazomethane (1ml) and were subsequently analysed 
on an AEI MS 12 mass spectrometer at 70eV. The mass spectra of 
the compounds were compared and fragmentation patterns derived.
4.2.6 Effect of rat gut microflora on bifluranol
Gastrointestinal contents were removed from the stomach,
upper and lower intestines and caecum of a male rat. E-Bifluranol
(40pg, 4pC) in ethanol (lOpl) was added to the contents (circa 0.3g)
o
from each part of the gastrointestinal tract and incubated at 37 C 
under nitrogen or air. After 3 days 0.3M HCl (3ei1) was added to the 
samples, which were extracted with ethyl acetate (3 x 3ml). The 
organic phase was reduced to dryness and t.l.c. characteristics 
following chromatography in solvent system (d) compared to those 
of metabolite 7 by t.l.c. radioassay.
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4.2.7 Microsomal incubations with bifluranol
Microsomes were prepared from male Biorex Wistar rats 
(200-250g). The animals were killed by cervical dislocation, the 
livers quickly removed, v/eighed and homogenised in ice cold 1 .13%
KCl (4 vol.). The homogenate was centrifuged at 4°C on a Mistral 6l 
centrifuge (high speed attachment) at 10,000g for 20 minutes and the 
supernatant centrifuged at 3 0 ,000g for 33^  hours to obtain a 
microsomal pellet. The microsomes were resuspended in a volume of 
0.03M tris pH7.4, 0.003M MgCl2 (assay buffer) equivalent to the 
original liver weight immediately prior to use. Microsomal 
incubation mixtures (in assay buffer, final vol. 3«lml) contained 
glucose-6-phosphate (8mg), nicotinamide (24mg) , NADF (2.3cig) , 
glucose-6-phosphate dehydrogenase (13E.Ü.) and microsomes (0.3ml,
6-8mg protein). Microsomal protein was determined by the method of 
Lowry, et a l , 1931, using bovine serum albumin standards. Control 
incubations using boiled microsomes, CO treated microsomes or no 
microsomes were included. Samples were incubated with shaking 
at 37°C under 95% 02/5% CO2.
The first experiment examined the time course of production
3 3 3of volatile H, aqueous H and H binding to microsomes in
incubations containing ^H-bifluranol (10,30 or lOOug/ml, 10pC in
20pl ethanol). 2 different microsomal preparations were used
and aliquots (0.5ml) of the incubation mixtures removed to 10%
trichloroacetic acid (0.3ml) at 0,20,43 and 90 minutes. The
microsomal protein precipitates were separated by centrifugation,
washed with ethanol (4 x 1ml), dissolved in lOM sodium hydroxide (1ml),
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3
neutralised with conc. HCl (1ml) and the H. content of the protein
determined. The aqueous phase was extracted (ethyl acetate,
3(4 X 2ml)) and the aqueous H content measured before and after 
drying. The ethanol washings and ethyl acetate extracts were 
combined, dried under nitrogen, reconstituted in ethanol (2ml) and 
the content of the organic phase measured.
3 3The H in the organic phase following incubation of H-
bifluranol with microsomes was examined by t.l.c. autoradiography
following chromatography in solvent systems d-f and the t.l.c.
characteristics compared with those of authentic bifluranol,
mono- and di-hydroxy bifluranol and metabolite 7*
3
A second experiment examined the binding of H-bifluranol to 
albumin with rat liver microsomes. Bifluranol (lOp^ml, 38pC) was 
incubated with two different niicrosomal preparations plus albumin 
(lOmg) for 90 minutes. The microsomes were removed by 
centrifugation at 30,000g for 3)^  hours and an aliquot (2ml) of the 
albumin containing supernatant added to a 1% charcoal suspension 
in 0.05M tris pH7.4 (2ml). After 30 minutes the charcoal was 
removed by centrifugation, the supernatant dialysed against water
3
(4 X 21) for 4 days and the H content of the albumin solution 
determined. A control which had not been incubated with microsomes 
was processed similarly.
A third experiment examined the effect of glutathione on the
3 "
extent of H-bifluranol binding to microsomes. Bifluranol 
(lOOpg/ml, 38pC) was incubated with microsomes and glutathione
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(0-2mg/incubation) for 90 minutes. Microsomal protein was
isolated following precipitation with an equal volume of 10%
3trichloroacetic acid and the H content determined as described 
in the first experiment.
4.2.8 Incubation of bifluranol with other oxidation systems
Attempts were made to produce metabolite 7 using hydrogen 
peroxide, tyrosinase (Westerfeld, 1940) or the Udenfriend system 
(Udenfrierid, et al, 1954).
^H-Bifluranol (1, 100 or 500pg, 19pC) in 0.005M sodium 
hydroxide pE8.5 (0.5ml) was incubated with 30?o w/v hydrogen 
peroxide (lOOpl) at room temperature for 2 or 24 hours. H 
content was determined before and after drying and the material 
examined by t.l.c. autoradiography following chromatography in 
solvent system (d).
^H-Bifluranol (1, 10 or lOOpg, 19pC) in 0.25M phosphate
PH6.5 (2ml) was incubated with tyrosinase (2mg) at 25°C for
0.5 or 2 hours under 95% 02/5% C02* Controls used boiled 
%
tyrosinase. H content was determined before and after drying 
and the material examined by t.l.c. autoradiography following 
chromatography in solvent system (d).
Bifluranol (l8mg in 0.1ml acetone) was added to O.IM 
phosphate buffer pH6.5 (3nil) containing ascorbic acid (25mg), 
EDTA (33mg) and ferrous sulphate (4mg). The bifluranol was
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largely insoluble. Aliquots (O.^Dil) were removed from the 
mixture after 0, 0.5, 1 and 2 hours, added to 2.5M HCl (1ml) and 
extracted with ethyl acetate (2ml). - The ethyl acetate extract 
was examined by t.l.c. and products visualised under ultraviolet 
light following chromatography in solvent system (d). The 
experiment was repeated using the same reagents in buffer (1.5ml) 
and adding the bifluranol (l8mg) in ethanol (1.5ml); this 
procedure ensured the bifluranol remained in solution.
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4.3 RESULTS
4 .3 .1  Mass spectral analysis of metabolite 7
The g.l.c. analysis of the trimethylchlorosilane derivatives 
of bifluranol and metabolite 7 gave retention times of l4 minutes 
and 27 minutes respectively. The radiochromatogram of metabolite 
7 showed a major peak was eluted from the g.l.c. at 27 minutes, 
corresponding to ^ 9 5 %  of measured ^H. No material corresponding 
to bifluranol was observed.
The mass spectrometry fragmentation patterns of the methyl 
ethers of metabolite 7, bifluranol and mono- and di-hydroxy 
bifluranol are presented in Figures 4.1 and 4.2. The results 
are interpreted in the discussion.
4 .3 .2  Effect of rat gut microflora on bifluranol
3
Between 95-97% of H was extracted with ethyl acetate from 
acidified incubations of bifluranol with stomach, intestinal or 
caecal microflora of rat. Radioassay of the extracted showed 
that 96-98% cochromatographed with bifluranol (Rf 0.55) iu 
solvent system (d), the remaining 2-4% being polar material at 
the origin of the chromatogram. No material corresponding to 
the t.l.c. characteristics of metabolite 7 (Rf 0.25) was seen.
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Fifçure 4.1 Molecular ion fragments of the methyl ether 
derivatives of bifluranol and metabolite 7» 
Mass spectra were obtained in an AEI MS 12 
mass spectrometer at 70ev .
bifluranol methyl ether100*
80-
I!
*
20"3b 320
200100
*/•
l67 metabolite 7 methyl etherlOOT T  «3
*
I•s
I 133
k
200100
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Figure 4.2 Molecular ion fragments of the methyl ether '
derivatives of mono- and di-hydroxy bifluranol. 
Mass spectra were obtained on an AEI MS 12 
mass spectrometer at 70ev
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4.5.3 Incubation of bifluranol with rat liver microsomes
The distribution of bifluranol between microsomes and the
organic and aqueous phases (volatile and non volatile) with time is
presented in Figure 4.5. Duplicate values were within the area
of the graph symbols unless otherwise indicated. The data show a
time dependent increase in the amount of associated with
5microsomes and in aqueous H (volatile anu non volatile),
3concomitant with a decrease in ethyl acetate soluble H. Control
incubations using boiled or carbon monoxide treated microsomes or
%
no microsomes showed that 99% of H was ethyl acetate extractable.
The analysis of ethyl acetate soluble radioactivity from
complete microsomal incubations by t.l.c. autoradiography (Table 4.1)
showed two discrete products were present plus polar material at
the origin of the chromatograms. However, none of these
cochromatographed with metabolite 7 in all systems. Two of the -
3components formed by incubation of H-bifluranol with rat
microsomes had similar t.l.c. characteristics to authentic mono-
and di-hydroxy bifluranol. The ethyl acetate extracts from
%
incomplete microsomal incubations with H-bifluranol only contained 
material with t.l.c. characteristics identical to bifluranol.
Albumin isolated from microsomal incubations with 
^H-bifluranol (lOpg) showed that 4% (5.5i4.5%) of bifluranol 
was associated with the albumin after charcoal absorption and 
dialysis v/hilst control samples showed retention of less than 
0 .1^ of ^H with albumin.
94
•H
O
C
(Q
U
3
rH
«H
•H
J
«H
O
c
o
•rt
4J
(3
■§
O
C
£
(6
V
■*iri
•H
<c
•H
k
c;
4-»
V
g
«
ü
DErj
o
c
k
3 ce
iH 3
E
•H O
J3 %
O
3 k
•H u
•H
% E
3
fct k
C Ürt >
Xi **4
ü rH
to
£
Sj*»4
V
H
•H+i
«
HO
>
rf
H
EOn
o
k
ü
•H
E
rf
gH
O
«
□ □
«
M
•H
fi
H
O
>
g
C
o
3
cr
fi
□ □
E
04J
V)
%fi
fi
+)
fi
fH
1
O
ü
H
O
(4fi
k
3
H
M
3,
O
O
§
■Pfi
>>fi
fi
+ifi
I
O
O
3
;
ü
•ri
rQ
H
M
è
o
fi H
l «■P fi
fi H
fi -H 
•P rD fi
%  E 
o 'm
= s
Efi
-Pfi
%fi
fi
■p
fi
A
Eo
u
H
bO
&
CO
-r*
•H
k
■P
fi
sc
r\
fibç
fi
p
3fi
ü
kfi
O  tr\ o O
(T. ^  CM-
O m  O 
ON -d* CM
O O O 0\ fi\ CT\ o lA Q oCA rC CM
9$
•H
iH
r -!
CO\Û
•H
•H
rH
«H
96
Table 4.1 Rf values for bifluranol and oxidation
products on silica >?el 60F 29^ thin layers 
Rf. in solvent systems
Component d e f
bifluranol 0.55 0 .2 8 0 .8 5
monohydroxy
bifluranol
0.43 0 .1 8 0 .8 2
dihydroxy
bifluranol
0.35 0 .0 8 0 .7 8
metabolite 7 0 .2 6 0 .15 0 .8 3
microsomal
incubation
products
0.43 * ' 
0.35
baseline
0 . 18 
0 .0 8
baseline
0 .8 3
0.79
baseline
solvent systems: (d) <40°petrol/ether/ethanoi (8/8/1)
(e) toluene/piperidine (5/2 )
(f) ethyl acetate/isopropanol/water (65/24/1 2)
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5 'The extent of binding of H to inicrosomes incubated with 
^H-bifluranol (100/ig) was progressively reduced with increasing 
amounts of glutathione (Figure 4.4).
4 .3 .4  Incubation of bifluranol with other oxidative systems
Incubations of ^H-bifluranol (l-300pg) with hydrogen 
peroxide or tyrosinase and subsequent t.l.c. analysis showed that 
the only materials present were bifluranol or polar material at 
the origin of the chromatogram. No material of intermediate
t.l.c. characteristics, as occurs with microsomal incubations,
• 5
was observed. Conversion of H-bifluranol to polar material
z
was complete at the lp.g level and between 37-61% of H was
3
volatile following incubation of H-bifluranol with hydrogen 
peroxide (2 and 24 hours) or tyrosinase (0.5 or 2 hours).
Incubation of bifluranol in the Udenfriend system and 
subsequent t.l.c. analysis of the products indicated the only 
materials present were bifluranol or polar material at the 
origin of the chromatogram.
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4.4 DISCUSSION
Metabolite 7 was shown to be fr.ee of bifluranol by g.l.c. 
prior to mass spectrometry of the methyl ether derivative. The 
fragmentation pattern (Figure 4.1) shows major peaks at m/e 
1 9 7, 1 8 3, 1 6 7, 153 and 139 while that of bifluranol methyl ether 
shows major peaks at m/e 167, 133 and 139. The fragmentation 
pattern of the methyl ether of monohydroxy bifluranol is similar 
to that of metabolite 7 , whilst that of dihydroxy bifluranol 
methyl ether shows major peaks at m/e 197 and I83 (Figure 4.2).
The proposed fragmentation pattern of the methyl ether of 
metabolite 7 is shown in Figure 4.5 and is based on metabolite 7 
methyl ether being derived from bifluranol by oxidation of one 
of the aromatic rings to give 2 isomers. This rationalisation 
of the fragmentation pattern of metabolite 7 methyl ether is 
supported by the similar fragmentation pattern of monohydroxy 
bifluranol methyl ether.
The fragmentation pattern of metabolite 7 does not give a 
parent ion at M"^  = 3 5 0, although it would be expected that this 
ion would be of low intensity. If metabolite 7 is a mixture 
of two isomers, homolytic fission would yield four peaks at m/e 
1 9 7, 1 8 3, 167 and 153 and this is observed. Loss of formaldehyde 
from m/e 197 and I83 would lead to peaks at m/e I67 and 1 5 3, 
enhancing those already obtained by homolytic fission. Subsequent 
loss of methyl or ethyl groups from m/e 167 and 153 would lead 
to m/e 139' The fragmentation patterns of the methyl ethers of 
bifluranol and the mono- and di-hydroxy derivatives can be
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similarly rationalised.
Studies with diethylstilboestrol (Metzler, 1976) indicate 
that aliphatic hydroxylation of the ethyl side chain of bifluranol 
is a possible site of oxidation. However, an aliphatic hydroxyl 
group would not be expected to react with diazomethane, but even 
if this grouping did methylate to give a total mass increase of 
3 0 , the fragmentation pattern would differ from that observed.
Whilst the fragmentation pattern of the methyl ether of 
metabolite 7 can be considered reasonably well defined, the 
actual identity of metabolite 7 prior to méthylation has not 
been clearly established. The difference in t.l.c. characteristics 
of metabolite 7 in solvent system (d) when compared to authentic 
monohydroxy bifluranol indicate that either the hydroxyl group 
is not at the 5 position in the aromatic ring or that metabolite 
7 is the result of méthylation of the primary oxidation product 
by catechol-O-methyl transferase.
Attempts to obtain metabolite 7 by vitro means were 
unsuccessful. Hydrogen peroxide, tyrosinase and the Udenfriend 
system all reacted with bifluranol to produce highly polar 
material. Microsomal incubations also produced highly polar 
material, and, in addition, gave two products which corresponded 
in t.l.c. characteristics to mono- and di-hydroxy bifluranol. 
However, no material corresponding to metabolite 7 was observed.
If metabolite 7 is the methylated catechol of bifluranol, the 
microsomal system used would not have been expected to carry out
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this reaction, since catechol-O-methyl-transferase is not a 
microsomal enzyme.
The ability of the microsomal preparations to bind 
^H-bifluranol to microsomes and albumin, and the reduction of 
the binding to microsomes by glutathione, indicate that the 
oxidation of bifluranol in this system may proceed via an arene 
oxide, since these experimental findings have previously been 
shown to be consistent with this mechanism of oxidation 
(Jerina and Daly, 19?4). The loss of ^ H  from bifluranol using 
hydrogen peroxide and tyrosinase reached a maximal value of 605^ , 
and with microsomes approached 30% (Figure 4.3). The implications 
of these figures in assessing the extent of oxidation of 
bifluranol by consideration of the extent of loss from the 
drug are considered in detail in Chapter 6.
Degradation of bifluranol by rat gut microflora was minimal 
( <^5%) in these studies, in contrast to the extensive degradation 
of diethylstilboestrol found using ruminant faeces (Aschbacher, 
1976). It is possible that the initial bacterial degradation 
of diethylstilboes trol is at th'e stilbene double bond, since none 
of the degradation products which these authors identified was 
a result of direct aromatic oxidation. The lack of the stilbene 
bond in bifluranol would preclude this route of oxidation and 
may explain the observed lack of degradation of bifluranol seen 
with rat gut microflora.
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5.1 INTRODUCTION
5.1.1 Conjugation reactions
Phase 2 conjugation with glucuronic acid is generally the 
most important conjugation reaction for foreign compounds.
Whilst several tissues have been shown capable of producing 
glucuronic acid conjugates (Aitio, 1974), notably the intestine 
(Powell, et al, 1974) and lung (Aitio, 1973)» the liver contains 
the greatest potential for this conversion (Dutton, et al, 1977). 
Diethylstilboestrol is excreted in rat bile predominantly as the 
monoglucuronide (Fischer, et al, 1966), although the major site 
of conjugation has not been established. Mouse liver is the 
major site of uptake of the drug (Shah and McLachlan, 1976)and 
rat liver has been shown to produce diethylstilboestrol 
glucuronide (Gabaldon, et al, 1968). Rat intestine has also 
been shown to conjugate diethylstilboestrol with glucuronic 
acid (Fischer, et al, 1973)#
Conjugation with sulphate is not as extensive as that with 
glucuronic acid, and whilst phenol is excreted in urine as 
glucuronide and sulphate conjugates (Capel, et al, 1972), 
diethylstilboestrol sulphate esters have been reported as 
excreted to only a small extent (see Figure 1.2). Whether this 
is a reflection of a lack of sulphate conjugation is not clear, 
since it has been shown that both mono- euid di-siilphate esters 
of diethylstilboestrol are not excreted in rat bile per se and 
undergo partial or complete desulphation and conjugation with
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glucuronic acid prior to excretion (Barford, et al, 19??a).
This inability of rat liver to excrete sulphate esters of 
diethylstilboestrol would not affect phenol, which undergoes 
urinary elimination. In contrast, although the major conjugation 
of phenolphthalein prior to biliary excretion is with glucuronic 
acid (Levine, et al, 1968), administered phenolphthalein 
disulphate is excreted unchanged in rat bile (Hirom, et al, 1972). 
Thus it is possible that sulphate conjugation of drugs could occur 
extensively in liver, but is not necessarily manifested in the 
, excretory products due to inability of the biliary excretion 
mechanism to cope with sulphate esters generally. Alternatively, 
competition between glucuronyl- and sulpho-transferase enzymes 
could depend on lipophilicity of a substrate, since 
glucuronyltransferase activity is located in the endoplasmic 
reticulum and phenol sulphotransferase activity in the aqueous 
phase of the cell.
Cellular p-glucuronidase activity is lysosomal and would 
not be expected to hydrolyse glucuronides in vivo, but 
arylsulphatase C has been.shown to be located in microsomes and 
to be capable of hydrolysing sulphate esters of diethylstilboestrol 
(Barford, et al, 1977a), However, phenolphthalein disulphate is 
not a substrate for this enzyme (Hirom, et al, 1972). Thus the 
final excretory products seen in bile arise from a complex 
interplay of substrate specificities for synthetic and hydrolytic 
enzymes and the ability of the biliary excretion mechanism to 
excrete a particular conjugate.
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5*1.2 Experimental approach
The development of the isolated perfused liver system 
(Curtis, et al, 1971) has enabled a more detailed examination 
of the metabolism of drugs to be made and the isolated rat liver 
has been used in these studies to examine the role of the liver as 
a site of metabolism of bifluranol. Methodology for determining 
the formation of glucuronide and sulphate conjugates of 
diethylstilboestrol has been reported (Quamrae, et al, 1971a) and 
has been extended in these studies to obtain comparative data for 
the conjugation of bifluranol and diethylstilboestrol with 
glucuronic acid and sulphate.
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5.2 EXPERIMENTAL
5.2.1 Materials
%
H-Bifluranol was the material described in sections 2.2.2 and
2.2.6. The following materials were purchased: Diethylstilboestrol
(monoethyl-l~^^C, 58mC/mmol. Radiochemical purity in solvent 
system (a) (section 5.2.5) was 93%.)(Radiochemical Centre,
Amersham, Bucks., England); bovine serum albumin (fraction V),
ATP, ÜDPGA, arylsulphatase from limpets (Type III) and 
diethylstilboestrol (Sigma Chemical Co. Ltd., Kingston, Surrey, 
England); Difco TC médium 199 without phenol red (Difco Labs., 
Detroit, Michigan, U.S.A.); gentamycin (Flow Labs., Irvine,
Ayrshire); heparin, p-glucuronidase and general chemicals 
(B.D.H. Chemicals Ltd., Poole, Dorset,’England); pentobarbitone 
sodium (Nembutal) (Abbot Labs., Queenborough, Kent, England); 
thin layer chromatography plates (Merck Type 5735) (Anderman and 
Co. Ltd., East Molesey, England). Triton toluene scintillant was 
prepared as described in section 2 .2 .5 .
5.2.2 Animals
An adult female Swiss Alpine goat v/as used as the donor of 
red blood cells for perfusion studies. Male Wistar rats 
(220-250g) v/ere used as liver donors for perfusion studies.
Male Biorex Wistar rats (230g) were used as liver donors for 
preparation of glucuronyl- and sulpho-transferase enzyme systems.
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5.2.5 Perfusion of isolated rat liver
The method used was that described by Brewster, et al, 1977 
using the apparatus shown in Figure 5«1«
3
Control blood and bile samples were taken and H-bifluranol 
(4 .15mg, 5 5.8pC in propylene glycol (0 .2ml)) was added to the 
perfusion mixing chamber. Bile samples were taken at 10 minute 
intervals up to 1 hour and then every 50 minutes up to 5 hours 
and the weight of bile recorded. Perfusate samples (0.5ml)
, entering and leaving the liver were taken at 2 ,5 ,8  and 10 minutes, 
and thereafter at the same intervals as bile samples. All samples 
were frozen prior to analysis. Perfusate flow rate through the 
liver was monitored throughout the experiment and perfusate 
haeraatocrit values determined at the start and finish of the 
perfusion. The perfusion was stopped after 5 hours and the 
remaining perfusate and liver retained for analysis. Three 
• isolated liver perfusion experiments were performed.
5.2.4 Determination of radioactivity in perfusate samples
Blood (20pl), bile (lOpl) and liver (10.0-10.2g) samples 
were prepared as described in section 2 .2 .8  and ^H content 
determined as described in section 2.2.5* The total ^H in bile 
and perfusate was determined from the weight of the bile sample, 
(assuming specific gravity = 1 .0 0) or assuming a perfusate 
volume of 100ml respectively. Blood samples (20;il) were also 
counted after drying over P^O^ for 4 days. The amount of
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bifluranol present in bile and blood at various times was
calculated and the content of liver obtained by difference.
?
The overall recovery of H was determined at the end of the
3experiment. The loss of H on drying of blood samples was taken
3as a measure of volatile production.
5 .2 .5  Examination of perfusate and biliary
All perfusate samples entering the liver and samples leaving 
the liver (one experiment only) up to 1 hour after the start of 
the experiment were brought to 505^  aq. ethanol, centrifuged 
(2000g for 5min.), the supernatant removed and the pellet washed 
with 50% aq. ethanol (5 x 0.2ml). The supernatant and washings 
were combined, perfusate and bile samples were chromatographed in 
solvent system (a) for t.l.c. radioassay before and after 
p-glucuronidase hydrolysis (24h) and bile samples chromatographed in 
solvent systems (a) and (b) for autoradiography (sections 5.2.5 and 
5.2.4). Rat bile samples (section 2.2.15) were chromatographed as 
reference standards. •Bile samples were also hydrolysed with 
p-glucuronidase and acid and examined by t.l.c. radioassay and 
autoradiography in solvent system (d). The conjugates of 
bifluranol were identified by virtue of their similar t.l.c. 
characteristics to those previously more rigorously examined in 
chapter 5 . The amount of each conjugate in the samples analysed 
was converted to ng equivalents of bifluranol from the specific 
activity of the bifluranol.
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5,2.6 Conjugation reactions of bifluranol and diethylstilboestrol
The methodology used was based on Quamme, et al, 1971a. Male 
rats (250g) were killed by cervical dislocation, the liver 
removed, weighed and homogenised in cold 0.15M tris pH7.6 (4 vol.). 
The homogenate was centrifuged at 4 C for 20 minutes at 10,000g 
and the supernatant centrifuged for 3)4 hours at 30,000g. The 
microsomes were resuspended in a volume of buffer equal to the 
original liver weight and the 1 0 3,000g supernatant diluted with 
buffer (4 vol.). Protein content was determined by the method 
of Lowry, et al, 1951, using bovine serum albumin standards.
Glucuronyltransferase incubations in O.lpM tris, 0.01^ MgClp 
pH7.6 (1.5ml) contained UDPGA (0.5pni6les) and microsomes (25pl, 
equivalent to 25mg liver). The incubation mixture was preincubated 
at 37^0 for 10 minutes, after which ^H-bifluranol (0,5pC) or ^^0- 
diethylstilboestrol (0.04-0.03/iC) in ethanol (lOpl) was added. 
Enzyme action was stopped by removing the samples to ice and 
adding benzene (2.5ml)* Control incubations contained no UDPGA.
Sulphotransferase incubations in 0.15M tris, 0.12M KpSO/^,
0.02M MgCl2 pH7*6 (Irai) contained ATP (lOpnoles) and 103$000g
supernatant (0.5ml, equivalent to 25mg liver). The incubation
mixture was preincubated at 37°C for 10 minutes, after which
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bifluranol (0.5pC) or C-diethylstilboestrol (0.04-0.05pC) was 
added in ethanol (lOpl). Enzyme action was stopped by removing 
the samples to ice and adding benzene (2.5ml). Control 
incubations contained no ATP.
Ill
The aqueous phases were extracted with benzene (4 x 2.5ml), 
the radioactivity content remaining after extraction determined 
and taKen as a measure of the amount, of conjugation. The amount 
of bifluranol or diethylstilboestrol conjugated was obtained by 
subtracting the control from the test values and using the 
drug specific activity to determine the nmoles of conjugate 
produced.
The rate of conjugation in the two enzyme systems was 
initially examined with respect to time with ^H-bifluranol (5.4 and 
V 54.2pM) and ^^C-diethylstilboestrol (4pM). On the basis of these 
results a ten minute incubation time was chosen for subsequent 
Kinetic studies.
I
^H-Bifluranol (5.4-34^) or ^^C-diethylstilboestrol (0.5“^pM) 
was incubated with the conjugating systems as described above for 
10 minutes. The amount of conjugation of each compound in each 
system at 5 different concentrations within the above ranges was 
determined. The nmoles of conjugate formed/mg protein/min. (V) 
was calculated and Lineweaver Burke double reciprocal plots of 
1/V against 1/S (S =% substrate conc., juM) constructed. Three 
determinations using different enzyme preparations were made and 
Km and Vmax values determined for each preparation.
The effect of UDPGA and ATP concentration on the rate of 
conjugation was determined using the highest levels of bifluranol 
(34pM) and diethylstilboestrol (4pM), with incubations containing 
three times the concentrations of UDPGA and ATP used for standard
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incubations. The amount of conjugation was compared with that 
found using the standard incubation system.
The radioactivity present in the aqueous and benzene phases 
at the limits of the concentration ranges studied was examined 
by t.l.c. radioassay following chromatography in solvent system 
(a) (section 3 .2 .3 ). Aqueous samples were also examined by 
t.l.c. radioassay following p-glucuronidase (glucuronyltransferase 
samples) and sulphatase or acid hydrolysis (sulphotransferase 
samples) as described in sections 3.2.3 and 3.2.4.
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5.3 RESULTS
3
5 .3 .1  Examination of perfusate and biliary H
The distribution of between the perfusate and bile, and
■ . 3 ^
after 30 minutes, by difference, the amount of present in the
liver (using the mean level of perfusate entering and leaving
the liver) was calculated for the three experiments. The amount
of volatile present in perfusate samples entering and leaving
the liver was determined from the loss on drying and subtracted
3from the H figures for perfusate and liver to give H values
i
for bifluranol associated radioactivity (Figure 5.2). The total 
measured recovery of at the end of the experiments was 9?tl%.
The average perfusate flow rate through the liver was 9 ml/min 
and % haematocrit values at the start and finish of the 
experiments were 27-29%.
Biliary excretion of bifluranol metabolites was determined 
on the basis of radioassay following chromatography in solvent 
system (a) and autoradiography in solvent systems (a) and (b) 
(section 3.2.3) and is based on comparison with Rf values of
metabolites more rigorously identified in section 3.3.1. Three
.
major metabolites (bifluranol and metabolite 7 monoglucuronides 
(Rf 0.43-0.48), glucuronide sulphate (Rf 0.31) and diglucuronide 
(Rf 0.22)) were found and the amount of each conjugate in each bile 
sample calculated from the distribution determined on radioassay. 
B i l e  samples were hydrolysed vd-th pTglucuronidase to give total 
material (94% by radioassay in solvent system (a)) corresponding to
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Figure 5.2 Distribution of H between perfusate, liver and 
bile in the isolated perfused rat liver.
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bifluranol and bifluranol monosulphate. Radioassay of
p-glucuronidase and acid hydrolysed bile chromatographed in solvent
%
system (d) showed 89-93% of H cochrpmatographed with bifluranol. 
Traces of material at Rf 0.4^* 0.37, 0.26 and at the origin of the 
chromatogram, corresponding to monohydroxy bifluranol, dihydroxy 
bifluranol, metabolite 7 and unidentified polar product(s) were 
observed by autoradiography (see section 4.3.3).
The appearance of the three major conjugates of bifluranol 
in bile during the three perfusions as calculated from radioassay 
is presented in Figure 3.3* The order of appearance of bifluranol 
metabolites in rat bile was monoglucuronide, glucuronide sulphate 
and diglucuronide. Bifluranol and the mono- and di-sulphate esters 
were not detected in the bile samples (<[ 3%)*
3Analysis of perfusate H entering the liver by t.l.c.
radioassay showed a rapid removal of biflursuiol from the perfusate
(Figure 3*4). The first conjugates observed had t.l.c.
characteristics similar to the monosulphate and monoglucuronide,
but by 60 minutes the major perfusate components were the
monoglucuronide and glucuronide sulphate. Only traces (<C 3%) of
3bifluranol disulphate were found. Analysis of perfusate H leaving 
the liver showed that less than 1% was bifluranol.
5
The concentration of bifluranol H in the perfusate, liver 
and bile compartments (Figure 3*5) shows that a considerable 
concentration gradient is established between these three 
compartments. However, whilst the elimination rate constants alter
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Figure 3,k Percentage composition of perfusate H
assessed by t.l.c, radioassay in n-butanol/ 
acetic acid/water (4/ 1/ 1)(n=3$ - S.E.M.)
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Figure 5*5 Concentration of- H-bifluranol in perfusate 
liver and bile compartments of isolated
perfused rat liver (n=^ 3
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in the order perfusate> liver >  bile, and indicate transfer 
from perfusate-Oliver->bile, these values are not significantly 
different. The 11 to 15-fold concentration gradient between 
perfusate and liver and the 13 to 24-fold concentration gradient 
between liver and bile produces an overall gradient approaching 
3000-fold between perfusate and bile.
5.3,2 Pharmacokinetics in the isolated perfused rat liver
5After 4o minutes less than 2% of perfusate H was unchanged 
bifluranol (Figure 5.4) and the rate of removal from the perfusate 
was shown to be a first order process by plotting In log 
^iflurano^ ^against time (t). Linear regression analysis 
(correlation coefficient = 0.999) gave the equation
In Ibiflurano^ ^  = -6.l8t + 8,478 
■
Thus for bifluranol in this system the elimination rate constant 
from the perfusate (K) was 6.l8/h,, the apparent concentration 
at zero time ( ^iflurano^ was 48,lmg/l, the apparent volume 
of distribution (Vd = dose (jig) + jbiflurano^ (pg/1)) was 
86ml and the clearance rate (Vd x K) was ^^ Iml/h, (0.8?6ml/min/g 
liver),
The elimination of bifluranol conjugates in bile is directly 
proportional to time from 20-90 minutes (Figure 5»3)» indicating 
that the excretion process is saturated, zero order and 
independent of the concentration of conjugates in liver plus
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perfusate. Linear regression analysis (correlation coefficient = 
0 .9 9 9) using the equation
y =- m x + c
where y = fig of bifluranol in bile at time t
f ■
m = elimination rate constant, K 
X = time (min) 
c = y at time 0
gave an elimination rate constant for all conjugates of. 
l8.4pg/min. Similar analyses for the excretion of 
monoglucuronide (10-60min., correlation coefficient = 0 .9 9 8), 
glucuronide sulphate (20-120min., correlation coefficient = 0.999) 
and diglucuronide (30-120min., correlation coefficient = 0.999) 
gave elimination rate constants of 4,6, 7.3» and 6.7p&^min. 
for the three conjugates respectively.
5 .3,3 Conjugation of bifluranol and diethylstilboestrol with 
glucuronic acid and sulphate
■ ■
The rate of conjugation of both bifluranol and 
diethylstilboestrol with glucuronic acid and sulphate was linear 
over the first 20 minutes incubation in the two enzyme systems.
On this basis an incubation time of 10 minutes was selected for 
all subsequent studies.
Lineweaver Burke plots of 1/V against 1/S (3 experiments)
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for bifluranol and diethylstilboestrol in both the 
glueuronyltransferase. (Figure 5.6) and sulphotraneferase 
(Figure 5.7) systems were plotted.
The amount of conjugates produced with increased concentrations 
of UDPGA and ATP (three times the concentration used in the 
standard incubation) was found to be increased, by up to 1596 of 
the amounts formed using the standard incubation. The Km and Vmax 
values quoted are therefore relative to the concentration of the 
second substrate used.
Analysis of the benzene and aqueous.phases of both 
conjugating systems.by t.I.e. radioassay following chromatography 
in solvent system (a) (sections 5.2.3 and 3.3.1) showed that the % 
only material present in the benzene layers had t.1.c* 
characteristics corresponding to bifluranol (Rf 0.85) or 
diethylstilboestrol (Rf 0.85) and that no material corresponding.., 
to bifluranol or diethylstilboestrol was present in the aqueous 
phases. Glucuronyltransferase aqueous samples contained a 
single main radioactivity band (Rf 0.45-0.50 for both drugs)$ 
which was labile to p-glucuronidase to give material with 
similar Rf values to bifluranol and diethylstilboestrol. 
Sulphotransferase aqueous samples contained a single mai.n 
radioactivity band (Rf 0.60-0.65 for both drugs) which was not 
labile to sulphatase but was labile to acid to give material 
with similar Rf values to bifluranol and diethylstilboestrolo
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5.4 DISCUSSION
Isolated liver perfusion studies have confirmed this organ 
as a major site of metabolism of bifluranol. Bifluranol is 
quantitatively removed from the perfusate on the first pass 
through the liver and is rapidly converted to sulphate and 
glucuronide conjugates. The first conjugates seen in the 
pgi*fusate are the monosulphate and monoglucuronide * but only the 
monoglucuronide appears in the bile. However, both these 
monoconjugates are substrates for further conjugation with 
glucuronic acid or sulphate, to give the glucuronide sulphate 
(by two possible routes) and the diglucuronide, which then appear 
in perfusate and bile in significant amounts « Little monosulphate 
or disulphate was seen in the perfusate and none in the bile.
The monoglucuronide of bifluranol is initially rapidly 
excreted in the bile, but is soon replaced as the major biliary 
conjugate by the glucuronide sulphate and diglucuronide. The large 
amounts of diglucuronide found in bile with the isolated rat liver, 
but not in vivo (Table 3«2), probably results from biliary excretion 
Having been saturated. This would leave any monoglucuronide in ti*e 
liver available for further conjugation.
Since the values for. biliary excretion rates are initially 
apparently zero order and nominally independent of conjugate 
concentration, it is possible that the differences in excretion 
rates may reflect the affinity of the conjugates for the biliary 
excretion raechanism(s). Alternatively the differences may arise
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from different concentrations of the three conjugates at the 
site of biliary excretion. Unfortunately it was impossible to 
determine the relative concentrations of the conjugates at the 
site of excretion. However, if one assumes that perfusate levels 
of conjugates reflect levels in the liver, then at 60 minutes the 
perfusion concentrations of diglucuronide, glucuronide sulphate 
and monoglucuronide are 1.3» 4.1 and 7.6pg/ml. Since the 
respective excretion rates are 6.7» 7*3 and 4.6pg/min, this 
implies that the diglucuronide has the highest affinity for 
excretion, followed by the glucuronide sulphate and then the 
monoglucuronide. This would mean that the sulphate moiety aids 
in biliary excretion, although in view of the lack, of excretion 
of mono- and di-sulphates of bifluranol the exact mechanism by 
which this may occur is unknown.
The only study using the isolated liver with 
diethylstilboestrol was in sheep (Huber, et al, 1972), where 76% 
of drug radioactivity was retained on a first pass through the 
liver. The radioactivity remaining in the perfusate after this 
passage contained diethylstilboestrol (39%) and its 
monoglucuronide (6l%). After 1 hour 99% of perfusate and 95% 
of liver radioactivity was present as conjugates, although only 
6% of radioactivity was present in bile. Thus whilst sheep livei 
effectively conjugates diethylstilboestrol, little biliary 
excretion occurs, in contrast to bifluranol in rat, where rapid 
conjugation and excretion in bile is ooserved.
Volatile ^H production (7%) was observed in the perfusate
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and t.I.e. examination of hydrolysed bile samples indicated the 
presence of mono- and di-hydroxy bifluranol and metabolite 7 
(see chapter 4). Thus the isolated liver is capable of oxidising 
bifluranol in a similar manner to microsomes vitro, and in
addition also produces metabolite 7.
The considerable concentration gradient between perfusate 
and bile is consistent with hepatic uptake, possibly by X and Y 
binding proteins (Reyes, et al, 1969î Takada, et al, 1974), and 
active transfer to the bile (Uesugi, et al, 1974). The ability 
of the liver to produce a concentration gradient approaching 
15-fold between liver and perfusate must account for the rapid 
uptake of bifluranol seen in autoradiographic studies and provides 
an explanation for the very low blood levels found in vivo 
(chapter 2).
The preliminary experiments carried out on the kinetics of 
conjugation of bifluranol and diethylstilboestrol may provide an 
explanation for the mixed double conjugate formation seen with 
bifluranol but not diethylstilboestrol in vivo. The lower Km 
value for glucuronyltransferase activity found with 
diethylstilboestrol (Km = 2.4) compared to the Km value for 
sulphotransferase activity (Km =- 11) indicates that under these 
experimental conditions diethylstilboestrol has a slightly higher 
affinity for glucuronidation than sulphation. By contrast the Km 
values obtained for bifluranol with glucuronyltransferase (Km = 12) 
and sulphotransferase (Km =l4) are similar and bifluranol has a 
similar affinity for both systems.
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The Vmax values for bifluranol conjugation are approximately 
ten times higher than corresponding values for diethylstilboestrol 
using identical enzyme systems. That bifluranol is conjugated 
with both glucuronic acid and sulphate at a considerably faster 
rate than diethylstilboestrol may provide a rationale for the 
excretion of diconjugates seen with bifluranol. However, the 
similar rates of formation of glucuronide (25mg equivalents of 
liver per incubation, Vmax = O.lnmoles/mg protein/min) and 
sulphate (25mg equivalents of liver per incubation, Vmax = 
0.15nmoles/mg protein/min) with diethylstilboestrol, but the 
lack of sulphate conjugate excretion vijro is a phenomenon 
similar to that found with oestrogens. Sulphate conjugates of 
oestrone are formed by liver slices in vitro (Brooks, e ^ a l, 1965)» 
yet sulphate conjugates are not excreted ^  vivo. Only small 
amounts of the glucuronide sulphate diconjugate are formed 
(Honma and Nambara, 1974).
Microsomal arylsulphatase C has been shown to hydrolyse
.
oestrogen and diethylstilboestrol sulphate esters (Barford, et_^,
1977a) and a comparison of the rates of hydrolysis of the sulphate 
esters of bifluranol and diethylstilboestrol is necessary before a 
clearer picture emerges to fully explain the diconjugate
formation and excretion seen with bifluranol. The implications
of these findings in the comparison of the overall metabolism of 
bifluranol and diethylstilboestrol are considered further in 
chapter 6.
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6.1 Introduction
The experimental studies in the preceding chapters have shown 
that the overall fate of bifluranol in vivo has many features in 
common with diethylstilboestrol and hexoestrol, although significant 
differences in metabolism have been found. These findings are now 
considered in more depth and the effects of the aromatic fluorine 
substituents on the metabolism of bifluranol examined.
6.2 Distribution of bifluranol
The pattern of distribution of bifluranol in mouse, rat and 
ferret is similar to that reported for diethylstilboestrol in mouse 
(Bengtsson and Ullberg, I9 6 3 ; Shah and McLachlan, 1976). Both 
drugs are extensively absorbed in all species studied, but systemic 
blood levels are low (Neumann, 1976) due to the high affinity of 
the liver for these compounds (Huber, et al, 1972), where a first 
pass effect removes the majority of drug from the circulation.
The initial uptake of unmetabolised drugs by the liver is 
possibly a function, in part, of their lipophilicity (Kurz, 1961). 
Both bifluranol and diethylstilboestrol are rapidly metabolised 
. to conjugates which, being less lipophilic, would be expected to 
diffuse out of the liver. However, the isolated rat liver 
perfusion studies with -^H-bifluranol showed the liver contained 
an 11 to 15-fold higher concentration of than perfusate. Studies 
with diethylstilboestrol in pregnant rats also showed a 10-fold 
concentration gradient between liver and perfusate. However,
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only small amounts of unconjugated diethylstilboestrol weie 
present in the liver (Fischer, et al, 1976), and it is reasonable 
to propose that bifluranol in the liver is present as conjugates 
after a short time, although this has not been measured directly.
The uptalee by the liver of organic anions has been attributed 
to two proteins, Y and Z, v/hich are not necessarily involved in 
the metabolism of drugs (Levi, et al, 1969; Reyes, et al, 1969» 
Takada, et al, 1974). These proteins have been shown to bind 
several organic anions, such as bilirubin, sulphobromophthalein 
and p-acetylaminohippuric acid. The sulphate esters of 
diethylstilboestrol have been shown to be rapidly taken up by the 
rat liver (Barford, et al, 1977^^) » and it is likely that the 
glucuronide and sulphate conjugates of diethylstilboestrol and 
bifluranol axe also bound to these proteins. Recently a protein 
with properties similar to Y protein has been isolated îrom rat 
liver, and in addition to binding organic anions also binds 
diethylstilboestrol with a similar affinity to that of steroid 
sulphates (Ketterer, et al, 1976). Thus it wouxd be reasonable 
to propose that the concentration of bifluranol and 
diethylstilboestrol and their conjugates by liver is primarily 
a result of binding to these proteins, although other binding 
sites, such as oestrogen receptors (Eisenfeld, et al, 1976) 
cannot be discounted.
Y binding protein has been shown to be more closely involved 
with the process of biliary excretion than Z protein, which appears 
to provide a hepatic pool of the drug (Takada, et al, 1974/. If
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an anion only binds to Y protein, then the concentration in bile> 
plasma^liver, whereas if binding to Z protein occurs as well the 
concentration in bile> liver> plasma. The experimental findings 
with bifluranol in the isolated perfused rat liver (Figure 5«5) 
are consistent with the binding of bifluranol and/or conjugates 
to Y and Z proteins.
Bifluranol was shown by autoradiography to be retained to 
some extent by the uterus and testes. Specific oestrogen receptors 
have been demonstrated in these and other tissues (Thomas, 1973i 
van Beurden-Lamers, et al, 1974), and this retention of bifluranol 
may be related to its oestrogenic properties. Similar localisation 
in uterus and testes has been shown with diethylstilboestrol 
(Bengtsson and.Ullberg, 1963; Sheridan, 1977), although uptake by 
the adrenal cortex of diethylstilboestrol and oestradiol 
(Ullberg and Bengtsson, 1963) also occurs and specific uptake 
by a tissue may not necessarily be related to the pharmacological > 
activity of a drug.
Bifluranol and diethylstilboestrol both cross the placental 
barrier and reach all tissues of the foetus. Fischer and coworkers 
(1 97 6) have shown that unconjugated diethylstilboestrol is the 
form in which this drug crossed the rat placenta, the conjugated 
drug being less readily available to the foetal compartment. 
Intravenously administered 'H-bifluranol readily crosses the 
placental barrier in mice, but there is a 4 hour delay before 
foetal is detected following oral administration. The reason 
for this difference has not been determined, although if a
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significant proportion of bifluranol H in the maternal blood is 
conjugated, as occurs with diethylstilboestrol (Metzler and 
McLachlan, 1978), this may explain the delay in transfer to the 
foetus. The distribution of bifluranol in the term foetus is 
similar to that of the adult, with hepatic uptake and biliary 
excretion being observed. Since the mouse foetus has the ability 
to conjugate diethylstilboestrol at day 16 (Shah and McLachlan,
1976) and unconjugated bifluranol does not cross the placental 
barrier so readily, foetal conjugation may be important in 
governing the distribution of bifluranol in the foetus at this 
stage of gestation.
Recently, concern has been expressed over the transplacental 
effects of diethylstilboestrol on the genital tract of offspring 
whose mothers took diethylstilboestrol during pregnancy (e.g. Bibbo, 
et al, 1973; Mattingly and Stafl, 1976; Herbst, 1976). Since 
diethylstilboestrol and bifluranol are both capable of crossing 
the placental barrier, it is worth considering how these lesions 
may arise. Both diethylstilboestrol and bifluranol are capable 
of undergoing oxidative metabolism via epoxides, which have been 
generally implicated in some aspects of cytotoxicity and 
carcinogenicity (see section 1.3)* The rodent foetus generally 
does not have the ability to carry out this type of reaction to 
any significant extent until birth (Anders, et al, 1973; Gillette 
and Stripp, 1973), and although this capability develops to around 
one third of adult levels during the first half of pregnancy in 
humans (Pelkonen, 1977), these enzyme activities are confined 
primarily to the liver, intestine and kidney (Pelkonen, et al, 1971)
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In view of the highly specific nature of the observed lesions, 
which seem to affect the development of the Mullerian cells during 
the first trimester of pregnancy, it is unlikely that oxidative 
metabolism, or the products thereof, would affect only these cells. 
Cytotoxicity arising from this mechanism is unlikely in this 
instance, although oxidative metabolism has been proposed as a 
possible mechanism for transplacental drug lesions (Pelkonen and 
Karki, 1975)o
Rodent studies have shown that both diethylstilboestrol and 
steroidal oestrogens are capable of producing transplacental 
abnormalities of the genital tract (Greene, et al, 19^0; McLachlan, 
et al, 1975; Vorherr, et al, 1976), similar to those found in 
humanso It is possible that oestrogenic stimulation of the 
Mullerian cells at a critical stage afLects the development of 
these cells, leading in females to incorrect formation of the, 
vagina and in some instances altered ability to respond to 
oestrogen stimulation at puberty.
This rationale would explain the high specificity of this 
lesion and seems to offer the best explanation for this aspect of 
diethylstilboestrol toxicity. Whether bifluranol, which is less 
oestrogenic than diethylstilboestrol, is capable of producing 
similar lesions has not been determined. However, in view of the 
findings with diethylstilboestrol, the ability of any drug with 
a high pharmacological activity to cross the placental barrier 
should always be carefully evaluated, and drug distribution studies 
are of considerable value in this respect.
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6.3 Phase 1 metabolism of bifluranol
6.3.1 Comparison with diethylstilboestrol
Examination of the rat biliary metabolites following 
administration of bifluranol shows that the drug undergoes less 
oxidative metabolism in rat than the 30% oxidation reported for 
diethylstilboestrol (Metzler, 1975» 1976). No evidence for 
significant oxidation of bifluranol was found in ferret and dog 
studies. Phase 1 metabolism of bifluranol in rat was found to 
involve oxidation of only one aromatic ring, in contrast to the 
more extensive hydroxylation of one or both aromatic rings of 
diethylstilboestrol and the aliphatic and stilbene oxidations 
(Figure 6.1).
The analysis of faecal and urinary H following H-bifluranox 
administration was only of a preliminary nature in these studies 
and did not exscnine these samples for Phase 1 metabolites. 
Consequently, the final excretory products in faeces and urine 
have not been identified.
The lower amounts of metabolite 7 found in rat bile 
following intravenous as opposed to oral administration of 
bifluranol is at present unexplained. This difference does not 
appear to arise from metabolism of bifluranol by gut microflora. 
The differences in collection times of bile (4 hours against 24 to 
72 hours respectively) may be of importance however, especially if 
metabolite 7 glucuronide is less readily excreted in bile.
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Figure 6,1 Comparison of sites of oxidation of 
diethylstilboestrol and bifluranol
aliphatic
hydroxylation
epoxidation
CH
CH
HO OH
CH
CH
a r o m a t i c  h y d r o x y l a t i o n
(one or both rings)
Diethylstilboestrol
CH CH
//
OH
Bifluranol
A R O M A T IC  H Y D R O X Y LA T IO N
(one ring only)
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Alternatively, oxidation during absorption may be an explanation, 
although the liver would be expected to be the major site of this 
reaction.
Bifluranol lacks a stilbene bond and consequently the 
oxidation reactions around the stilbene bond seen with 
diethylstilboestrol do not occur. No evidence was obtained to 
indicate oxidation of the aliphatic methyl and ethyl groups of 
bifluranol. Metzler and coworkers (1975-1978) have shown that 
in rat the major oxidation products in bile arise from ring 
hydroxylation, whereas in mouse, primates and humans the major 
products of oxidation seen in urine involve the stilbene bond 
and ethyl side chains. Whether this arises from analysis of 
biliary as opposed to urinary metabolites or represents species 
differences is unclear at present. If this difference is species 
dependent, then bifluranol would be expected to undergo less 
Phase 1 metabolism than diethylstilboestrol in man, as it lacks 
the stilbene bond.
6.3*2 Mechanism of bifluranol oxidation
3The observation that no volatile H or phase 1 biliary 
metabolites were found in ferret and dog, whereas volatile and
a phase 1 metabolite were found in rat, indicates that these two 
processes are linked. As outlined in chapter one, arene oxide 
formation has provided a rationale for many of the oxidation 
products of aromatic structures found in vivo (see Figure 1.5)*
A pathway for bifluranol oxidation is proposed (Figure 6.2),
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based on the assumption that this oxidation occurs by a similar 
mechanism. The production by microsomes of volatile and the
preliminary identification of mono- and di-hydroxy bifluranol by
%
t.l.c., the binding of bifluranol E to protein and the reduction 
of this binding by glutathione, are all in agreement with the 
proposed pathway for bifluranol oxidation. This mechanism, and
'■ 3-
the characteristics of the urinary volatile H (section 3.3»2), 
indicate that ^H20 is produced during oxidation of bifluranol. 
Glutathione conjugation arising from this mechanism of oxidation 
would be expected to occur, although this was not detected in vivo,
The Phase 2 méthylation of the catechol arising from the 
initial oxidation of bifluranol has not been conclusively 
demonstrated. Hov/ever, the lack of similarity of t.l.c. data for 
monohydroxy bifluranol and metabolite 7, but similarity of the 
mass fragmentation patterns of the methyl ethers of the two 
compounds, and the reported méthylation of diethylstilboestrol 
catechols (Engel, et al, 1976; Sossi and Dingell, 1978) indicates 
that metabolite 7 is monomethcxylated bifluranol. The presence 
of volatile , metabolite 7 and mono- and di-hydroxy bifluranol 
in the isolated rat liver.indicate that this organ is a site of 
bifluranol oxidation, although this reaction may also occur in 
other tissues.
Volatile production in 96 hours) and the amount of
metabolite ? found (4^ in 72 hour bile) in vivo are similar, but
do not represent the true extent of.oxidation of bifluranol. If
■3it is assumed that the production of K2O ^  vivo is essentially
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complete within a few hours, as was seen in the isolated liver
3
perfusion (Figure 5*2), and taking a half life for H2O in rat 
of 80 hours (D.J. Easter, personal communication), the true loss 
of from bifluranol in intact rats is about 8% and compares to 
79^  ^H20 in the isolated rat liver. Empirically this indicates a 
level of oxidation of 8% ^  vivo «
However, it is not possible to obtain an accurate measure 
of bifluranol oxidation, for whilst the percentage of biliary
corresponding to metabolite 7 is 4% (based on measuring up to 
87% of the administered dose in bile) the amount of this metabolite 
and the true extent of oxidation cannot be determined because of 
the NIH shift. The consequence of this mechanism in the case of 
bifluranol (Figure 6.3) is that the aromatic H can either be 
eliminated during oxidation or transferred to an adjacent carbon 
atom.
It has been proposed that the NIH shift involves a cationic
3
intermediate which may either losev^H directly to the solvent or 
rearrange to a cyclohexadienone, which enolises with the loss 
of hydrogen or \  (Guroff, et al, 1967)* This énolisation 
reaction can proceed with a significant isotope effect, where 
loss of H > D > T  (Boyd, et al, 1972), although hydroxylation of 
deuterated phenols r.nd halobenzenes occurred without a significant 
isotope effect (Tomaszewski, et al, 1973)* Whether an isotope 
effect occurs v/ith bifluranol has not been, established. However, 
this would only affect the retention or migration of H in the 
drug and the extent of hydroxylation of bifluranol would not be
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altered, since the initial hydroxylation reaction is the rate 
limiting step (Boyd, et al, 1972).
The extent of migration of label in aromatic structures is 
governed to some degree by the ability of substituent groups to 
stabilise a cationic intermediate. Halogen substituents can 
lead to migration and retention of label, whereas phenols readily 
lose label to the solvent (Daly, et al, 19^7, 1968a). The 
combined effects of fluorine and hydroxyl groups in bifluranol 
is difficult to predict, although later considerations indicate 
that the aromatic rings are electron deficient and label 
would be lost rather than retained.
Aromatic fluorine substituents have been shown to be lost 
during hydroxylation of 4-fluoroaniline and phenylalanine 
(Guroff, et al, 1966, 1967; Daly, et al, 1968b), although 
hydroxylation of fluorob'enzene and 4-fluorobiphenyl did not result 
in loss of fluorine (Daly, et al, 1969; Tomaszewski, et__al, 1975)* 
No loss of fluorine from bifluranol was observed in these studies.
A consideration of the hydroxylation of several aromatic 
structures indicates that the mechanism of oxidation is via a 
weak electrophilic substitution reaction (Daly, et al, 1968a).
Thus for both bifluranol and diethylstilboestrol the phenolic 
hydroxyl groups will be ring activating and ortho/para (3/5) 
directing, whilst the fluorine atoms of bifluranol are ring 
deactivating and meta (5) directing (Figure 6.4 for numbering)
(see Williams, 1969). Furthermore, it has been proposed that
142
fluorine can block oxidation at the site of substitution 
(Daly, et al, 1968b), which would imply that oxidation at the 
3 position of bifluranol cannot occur. Studies with
2-fluoroanisole showed that hydroxylation at the 6 position was 
greatly reduced compared to anisole (Daly, 1970), and if a similar 
effect occurs with bifluranol 5 hydroxylation would also be reduced. 
Bifluranol hydroxylation would thus be expected primarily at the 3 
position and would be reduced relative to diethylstilboestrol.
Hammett (1940) derived a series of substituent constants 
relating to the electronic effects of aromatic substituents and 
these constants are applicable to reactions whose rate depends 
on the degree of electron withdrawal or release by a substituent. 
The use of these constants, and similar values for aliphatic 
groups (Taft,1956), has been reviewed by Tute (1971) and the 
appropriate values applied to bifluranol and diethylstilboestrol 
to assess the relative reactivities of the aromatic rings of the 
two drugs towards hydroxylation (Figure 6.4). Both bifluranol 
and diethylstilboestrol have increased electronegativity relative 
to benzene and would be expected to more readily undergo 
oxidation by electrophilic substitution. However, this effect 
is much more pronounced with diethylstilboestrol (-O.6 5) than 
bifluranol (-O.I6 ) and this may contribute towards the reduced 
oxidation of bifluranol when compared to diethylstilboestrol,
•5
Experimental results with H-bifluranol show that approaching 
30% of H becomes volatile following oxidation with microsomes 
(Figure 4.3)« Since material with similar t.l.c. characteristics
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to dihydroxy bifluranol v;as seen on autoradiography, the oxidation
3
of both aromatic rings of bifluranol allows some retention of E 
during oxidation and the NIH shift therefore occurs to some extent, 
The polar material found at the origin of t.l.c. chromatograms 
has not been characterised, but may arise from further oxidation, 
quinone formation or polymerisacion. This material still contains 
and whether it arises from combination of unmetabolised 
bifluranol with oxidation products has not been established.
Thus, whilst volatile production is associated with bifluranol 
oxidation, the extent of oxidation of bifluranol cannot be readily 
deduced from volatile H measurements made in these studies.
From the preceding discussion, metabolite 7 from the in vivo
3
studies may therefore contain between one and two H atoms, 
depending on whether the hydroxylation of one of the aromatic
3
rings leads to complete loss or retention of H. If retention
3 ■is complete (which is unlikely in view of E^O in the urine), 
then the figure of 4% of biliary is accurate, whilst if loss
3 ■
of H is complete the drug specific radioactivity will have been 
halved and the value of 4$ of biliary will correspond to a 
true figure for metabolite ? of 8%.
Thus, whilst the bifluranol and diethylstilboestrol data are 
not strictly comparable, the figure of 4-8% for oxidation products 
of bifluranol in rat bile (C.2-20mg/kg) is significantly lower than 
the 30% reported following intraperitoneal-administration of 
diethylstilboestrol (lOmg/kg)(Metzler, 1973,1976). However, the 
total extent of bifluranol oxidation has still to be established.
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To summarise therefore, the reduced aromatic oxidation by 
rat of bifluranol compared to diethylstilboestrol may be explained 
in terms of the following:
a) The aromatic fluorines of bifluranol block two of the four 
probable sites of ring oxidation,
b) The fluorine substituents reinforce the directing effect of 
the hydroxyl group for substitution at the 3 position, but only 
by. a ring deactivating mechanism which reduces the reactivity 
for electrophilic substitution at this position.
Further studies on the kinetics of hydroxylation of bifluranol 
and diethylstilboestrol by microsomes to examine the above 
theoretical considerations will be of considerable interest.
6.4 Conjugation of bifluranol and diethylstilboestrol
The major site of conjugation of bifluranol in vivo has not 
been established, and although the isolated perfused rat liver has 
been shown to produce similar conjugates to those in the intact 
animal, several other sites in the body are capable of performing 
similar conjugation reactions. Whilst the organ with the highest 
potential for conjugation is the liver, in recent years the 
intestine has been shown to extensively conjugate several phenolic 
compounds (Fischer and Millburn, 1970; Riegelman and Rowland, 1973; 
Powell, et al, 1974; Bock and V/inne, 1973» Landsberg, et al, 1973)» 
The glucuronidation of diethylstilboestrol-by rat small intestine 
is extensive, and whilst no sulphate conjugation has been reported, 
the ability of the intestine to produce sulphate conjugates with
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phenol indicates that similar studies with bifluranol would be of 
considerable interest.
The conjugation of bifluranol with glucuronic acid and sulphate 
by rat, ferret and dog also occurs with phenol in these species 
(Capel, et al, 1972)« Both bifluranol and diethylstilboestrol 
undergo extensive conjugation of one of their two phenolic hydroxyls 
with glucuronic acid. However, the second hydroxyl group in 
bifluranol is also extensively conjugated, varying from 50% in 
rat to 89% in dog and 96% in ferret. This second conjugation is 
primarily with sulphate, although other conjugations also occur 
(Figure 6.5), Since the monoglucuronides of both bifluranol and 
diethylstilboestrol are readily excreted in rat bile, the 
conjugation of the second hydroxyl of bifluranol serves no 
apparent function.
No sulphate conjugates of diethylstilboestrol have been 
reported in rat bile (Fischer, et al, I9 66), although the present 
studies have shown that diethylstilboestrol is conjugated with 
sulphate ^  vitro, confirming previous results for the production 
of diethylstilboestrol sulphate by rat liver (Payne and Mason,
1963), The sulphate esters of diethylstilboestrol are not 
excreted in rat bile per se following intravenous administration. 
The disulphate is partially desulphated and then conjugated with 
glucuronic acid prior to excretion as the glucuronide sulphate, 
whilst the monosulphate is either desulphated or conjugated with 
glucuronic acid (Barford, et al, 1977a), Thus even when sulphate 
esters of diethylstilboestrol are available in rat liver, these
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are rapidly hydrolysed. By contrast, studies in’ guinea pig 
following administration of diethylstilboestrol showed the 
excretion of a glucuronide sulphate in bile, which was attributed 
to the low level of arylsulphatase C in liver (Barford, et al, 
1977b).
The phenol sulphotransferase enzymes are present in the cell 
cytosol and it would appear that there are at least three distinct 
sulphotransferase enzymes (Barford and Jones, 1971; McEvoy and 
Carroll, 1971). These enzymes catalyse the sulphation of phenols, 
phenolic steroids and L-tyrosine methyl ester. The present studies 
were carried out with a crude enzyme preparation and no attempt
I
to characterise the enzyme responsible for sulphation of bifluranol 
and diethylstilboestrol has been made.
Bifluranol is conjugated with sulphate in vivo and in vitro. 
The enzyme system used in vitro has a similar Km for sulphation 
of bifluranol and diethylstilboestrol, but the Vraax value for 
bifluranol is twelve times higher than that for diethylstilboestrol 
If this difference also occurs ^  vivo, the amount of bifluranol 
sulphate ester formed would be higher than for diethylstilboestrol. 
However, whether this would lead to a higher availability of 
sulphate ester for excretion cannot be concluded from the present 
studies as the rate of breakdov/n of bifluranol sulphate is 
unknown, and further work in this area is necessary.
Diethylstilboestrol has a 3 to 4-fold higher affinity for 
glucuronyltransferase than bifluranol, as measured by Km values.
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and further studies are needed to establish whether this difference 
is significant. However, the bifluranol glucuronidation rate is 
twelve times faster than diethylstilboestrol, and extrapolation 
of these differences to the in vivo situation is difficult. 
Diethylstilboestrol glucuronidation by female rat liver microsomes 
gave a conjugation rate for diethylstilboestrol of lOnmoles/mg 
protein/min. (Lucier and McDaniel, 1977), compared to a rate of 
O.llnmoles/mg protein/min. in these studies. The concentration of 
diethylstilboestrol used was 100-fold higher and female rats were 
used in the published study. Whether this higher rate is due to a 
concentration effect on the microsomal membrane or a sex difference 
is unknown. These widely differing results emphasise the 
difficulties in obtaining meaningful comparative data between 
studies.
The differences in the glucuronidation kinetics of bifluranol 
and diethylstilboestrol may arise from different
glueuronyltransferase activities, as has been reported for several 
drugs and endogenous compounds (Jacobson, et al, 1973: Hao, et al, 
1977; Fuchs, et al, 1977). However, comparison of the 
glucuronidation rates of o-sminophenol and p-nitrophenol has been 
interpreted both in terms of single and different enzyme activities 
(Howland, et al, 1971: Howland and Bohm, 1977; Burchell, 1977). 
Caution is necessary at present in ascribing heterogeneity to 
glueuronyltransferase activity and the detailed nature of this 
enzyme system is still unknown (Dutton and Burchell, 1977).
Differing methods of preparation and measurement of
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glueuronyltransferase often make direct comparisons between 
studies difficult, although a comparison of glueuronyltransferase 
activity towards a number of phenols*has indicated some factors 
which affect the rate of glucuronidation (Mulder and van Doom, 
1975)• Low lipid solubility is generally accompanied by a low 
glucuronidation rate, but other factors determine the rate with 
highly lipid soluble compounds. Bulky ortho substituents reduce 
glucuronidation, whilst electron donating or withdrawing 
substituents increase conjugation. Since both bifluranol and 
diethylstilboestrol are readily lipid soluble and steric 
hinderance factors are similar, the observed differences in 
glucuronidation rate may arise from the aromatic fluorine 
substituents of bifluranol, in analogy to the increased rate of 
glucuronidation of 2-chlorophenol compared to phenol.
6 .5  Excretion of bifluranol
The major excretory pathway of bifluranol in mouse, rat, 
ferret and dog was via the bile and faeces, with only small amounts 
appearing in the urine. This is similar to the pattern of 
excretion of hexoestrol and diethylstilboestrol in most species 
(see section 1.2). Removal of drug from the blood and uptake by 
the X and Y proteins of liver has already been discussed, whilst 
transfer of drugs into the bile has yet to be fully explained.
It has been proposed that biliary elimination may be, in part, 
the result of selective reabsorption from a primary bile, 
whereby low molecular v/eight compounds are reabsorbed and high
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molecular weight compounds are retained (Clark, -et al, 1971)* 
Studies on the absorption of compounds following retrograde 
biliary administration indicates that lower molecular weight 
compounds more readily disappear from the biliary tree 
(Peterson and Fujimoto, 1975), although other studies demonstrated 
considerable uptake of the high molecular weight phenolphthalein 
glucuronide administered by this route (Gustafson and Benet, 1974). 
The concept of a bi-directional exchange of solute within the 
biliary tree has been proposed to account for the biliary 
secretion of intravenously administered compounds during 
occlusion of the bile duct (Peterson and Fujimoto, 1975)*
However, all these studies involve techniques which are not 
physiological and at present this concept is unproven.
A second mechanism has been proposed involving active 
transport of anions into the bile. The biliary excretion of 
glucuronides has been shown to occur against a high concentration 
gradient by a process which is saturable and subject to 
competition from other anions (Uesugi, et al, 1974), and other 
studies showing active transport of bile acids, drugs and steroids 
have been reported (Despopoulos, 1970; Ertmann and Damm, 1975)* 
Powell and coworkers (1975) examined the biliary excretion of 
phenolphthalein disulphate using a constant infusion technique 
and demonstrated competition for excretion by other glucuronide 
and sulphate conjugates. Later studies examined the rate of 
excretion in relation to infusion rate and a two compartment open 
model system for biliary excretion was found to be appropriate 
(Powell, et al, 1975)*
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The isolated liver perfusion studies with bifluranol show 
that biliary excretion establishes a considerable concentration 
gradient between perfusate and bile, and that the excretion of 
conjugates is zero order during the first hour of perfusion- The 
biliary excretion of the three conjugates of bifluranol is not 
inconsistent with competition between the conjugates for excretion. 
These results are more indicative of an active transport process, 
since selective reabsorption of low molecular weight material 
would not limit the rate of biliary excretion of conjugates or 
indicate competition for biliary excretion.
Sperber (I965) noted that renal tubules secrete compounds in 
the molecular weight range 200-400, whereas compounds of higher 
molecular weight are excreted in bile. The concept of a threshold 
molecular weight for biliary excretion of organic anions has been 
developed on the basis of several studies (Abou el Maxarem, et al, 
1 96 7; Millburn, et al, 1967; Hirom, et al, 1972, 1976, 1977). 
Molecular weights ranging from 325-50 in rat up to 500 for man 
and rabbit have been proposed as necessary for biliary excretion.
The high affinity of-liver for bifluranol and its conjugates, 
and the low systemic blood levels, indicate that the low levels of 
bifluranol excretion in urine found in these studies reflects 
glomerular filtration of drug and conjugates from the blood. 
Bifluranol (M.Wt.292) is extensively excreted in rat bile, primarily 
as the monoglucuronide (M.Wt.469) and glucuronide sulphate 
(M.Wt.5 4 9). The major conjugates in ferret and dog are also 
glucuronides, but in these species diconjugates with sulphate.
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and possibly phosphate, yields conjugates of M.V/t. >500 and these 
are eliminated in bile.
The final excretion of bifluranol in the species studied is 
predominantly via the faeces, with less than 8% appearing in the 
urine. However, faecal elimination is delayed considerably in 
rat, and to a small extent in ferret, by enterohepatic circulation. 
Whether this difference in the extent of delay is due to 
differences in the pattern of biliary conjugates, gut microflora 
or some experimental physical factor such as intestinal motility 
has not been established. Enterohepatic circulation of 
diethylstilboestrol also occurs extensively in rat (Fischer and 
Weissinger, 1972; Fischer, et al, 1975) although the final 
excretion, as with bifluranol, is eventually via the faeces.
6 .6  Bifluranol in man
No animal species, has yet been shown to be an accurate guide 
to the metabolism of drugs in man, although primates appear to 
be most closely related (Smith and Caldwell, 1977)• However, 
comparison with the known-routes of metabolism and excretion of 
diethylstilboestrol and oestrogens can provide some indication of 
the likely fate of bifluranol in man.
In rat oestrone, oestradiol, oestriol and 
diethylstilboestrol are extensively eliminated in bile (Fischer, 
et al, 196 6; Sandberg, et al, 1967; Bolt and Remmer, 1972) and a 
similar picture is seen with oestrogens in man (Sandberg and
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Slaunwhite 1957, 1965; Stoa and Levitz, 1968). Excretion in rat 
is predominantly via the faeces with oestrone arid, 
diethylstilboestrol, whilst urinary excretion predominates with 
oestrone and oestriol. However, overall recoveries were incomplete, 
with oestrone and oestriol showing the lowest recoveries. In man 
the oestrogens are excreted in the urine, with only trace amounts 
appearing in the faeces (Beer and Gallagher, 1955), whereas
diethylstilboestrol is excreted in similar amounts in urine and 
.
faeces (Fischer, et_^, 1976; Metzler, 1976).
Extensive oxidative metabolism has been reported for 
oestrogens in rat (Nambara, et al, 1974; Honma and Nambara, 1974; 
Menzies and Watanabe, 1976) and for oestradiol in man (Adlercreutz 
and Luukkainen, 196 7). The extensive oxidation of 
diethylstilboestrol in rat is lower in man and confined to the 
stilbene bond and aliphatic side chains (Metzler, 1976).
Conjugation of the oestrogens and diethylstilboestrol in rat and 
man is primarily with glucuronic acid (Sandberg and Slaunwhite, 
1957; Stoa and Levitz, 19 6 8; Bolt and Remmer, 1972; Fischer, et al, 
19 6 6, 1 9 7 6; Bartke, et al, 1971; Metzler 1976; Menzies and 
Watanabe, 197 6), although oestriol in man is of particular 
relevance to bifluranol as the major biliary metabolite is the
3-sulphate-l6-glucuronide. This diconjugate appears in small 
amounts in urine, where the major conjugate is the l6-glucuronide, 
together with small amounts of 3-glucuronide formed by the 
intestine. The monoglucuronides are apparently poor substrates 
for biliary excretion.
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Interpreting this data in relation to the possible fate of 
bifluranol in man, extensive absorption, and possibly intestinal 
conjugation with glucuronic acid, would be anticipated. Oxidative 
metabolism would be expected to be low in view of the aromatic 
fluorine substituents and the absence of the stilbene bond of 
diethylstilboestrol. Conjugation with glucuronic acid and sulphate 
woùld be the major routes of metabolism, and monoconjugates with 
glucuronic acid or sulphate would be eliminated in the urine. 
However, the majority of the drug would be expected to form 
diconjugates which would undergo extensive enterohepatic 
recirculation. In view of the considerable faecal excretion of 
diethylstilboestrol compared to the oestrogens, and the extensive 
biliary excretion of bifluranol which would be expected to occur, 
faecal elimination of bifluranol would be expected to be high.
6.7 Future studies
The most interesting aspect to arise during these studies 
with bifluranol was the extensive diconjugate formation in rat, 
ferret and dog. Further studies using rat hepatocytes and 
arylsulphatase C preparations are necessary to obtain a clearer 
understanding of the reasons for glucuronide sulphate formation. 
Firm identification of the proposed glucuronide phosphate found 
in ferret and dog and examination of the mechanism of phosphate 
conjugation would be of interest in examining this species 
difference with rat. The conjugation and biliary excretion of 
bifluranol and diethylstilboestrol in species which are known to 
have specific liver enzyme déficiences, such as the cat and
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pig (Capel, et al, 19?4b), would provide comparative data on the 
effects of the fluorine substituents on conjugation reactions.
Comparative studies on the mode of action of bifluranol and 
diethylstilboestrol would be of considerable interest in view of 
their differing spectra of pharmacological activity. In rodents 
bifluranol and diethylstilboestrol are equivalent anti-androgens 
by the oral and intravenous routes, yet bifluranol has only one 
eighth of the oestrogenic activity of orally administered 
diethylstilboestrol. Since the distribution of the two drugs 
is essentially similar, the difference in pharmacological 
activity may arise from the different conjugation patterns of the 
drugs following first pass metabolism by the liver after oral 
administration.
At present there is considerable concern over metabolism 
mediated toxicity of drugs, especially those, such as the oral 
contraceptives, which are taken for a considerable period of time. 
Many drugs have been shown to undergo oxidative metabolism and 
tissue binding (Gillette, 1974), which in the long term may lead 
to tissue abnormalities. .The reduced hydroxylation of bifluranol 
compared to diethylstilboestrol, which is in part a result of the 
fluorine substituents, indicates a potential application in the 
design of new drugs, whereby undesirable hydroxylation reactions 
of known drugs may be reduced or eliminated. Furthermore, the 
pharmacological action of known compounds may be usefully 
altered by such modifications.
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